Stockwinners Market Radar for October 13, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:16 EDT AT&T to start iPhone 12 orders on October 16th - The company states: "AT&T is bringing our customers the new iPhone 12 lineup, including iPhone 12 Pro, iPhone 12 Pro Max, iPhone 12, and iPhone 12 mini, introducing a powerful 5G experience with the ability to tap into the power of our fast, reliable and secure nationwide AT&T 5G network. With a beautiful all-new design, iPhone 12 models feature unparalleled new camera systems, edge-to-edge Super Retina XDR display for a more immersive viewing experience with the Ceramic Shield front cover, and Apple-designed A14 Bionic chip, the fastest chip in a smartphone. Starting Oct. 16, AT&T customers can pre-order iPhone 12 Pro and iPhone 12 at www.att.com with online and in-store availability starting Oct. 23. AT&T customers will be able to order iPhone 12 Pro Max and iPhone 12 mini beginning on November 6, with availability on November 13. And, in an unprecedented move, new and existing customers can now get the iPhone 12 for $0 when they buy on a qualifying installment plan with an eligible unlimited plan."

18:04 EDT SJW Group's Texas unit files to buy the Clear Water Estates Water Systems - SJW Grou announced that its Texas subsidiary, SJWTX Inc., which does business as Canyon Lake Water Service Company, is planning to acquire the Clear Water Estates Water System in Canyon Lake, Texas. The companies have filed an application with the Public Utilities Commission of Texas, or PUCT, for approval of the transaction. The PUCT's decision on the application is expected in the first quarter of 2021. If approved by the PUCT, this would become the 13th acquisition by SJWTX since 2006.

17:47 EDT Altair holder George Christ sells over $2M in shares - Altair holder George Christ sold 45,180 shares between October 9 and October 12 for $45.44 per share, for a total transaction value of $2,053,011.

17:26 EDT CFPB orders Nissan auto financing unit to pay $4M over improper repossessions - The Consumer Financial Protection Bureau issued a consent order against Nissan Motor Acceptance Corporation, an auto financing subsidiary of Nissan North America, Inc., which services auto loans and leases originated by Nissan and Infiniti dealerships nationwide. Nissan's servicing operations are headquartered in Irving, Texas. The Bureau found that Nissan and its agents: wrongfully repossessed vehicles; kept personal property in consumers' repossessed vehicles until consumers paid a storage fee; deprived consumers paying by phone of the ability to select payment options with significantly lower fees; and, in its loan extension agreements, made a deceptive statement that appeared to limit consumers' bankruptcy protections. These actions violated the Consumer Financial Protection Act's prohibition against unfair and deceptive acts and practices. Today's consent order requires Nissan to provide up to $1 million of cash redress to consumers subject to a wrongful repossession, credit any outstanding account charges associated with a wrongful repossession, and to pay a civil money penalty of $4 million. It also imposes certain requirements to prevent future violations and remediate consumers whose vehicles are wrongfully repossessed going forward. The Bureau specifically found that, from 2013 through September of 2019, Nissan repossessed hundreds of consumers' vehicles despite the consumer having made payments or otherwise taken actions that should have prevented the repossession. The Bureau also found that, from at least early 2014 through late August 2017, Nissan's repossession agents, with Nissan's knowledge, demanded that consumers pay a separate, upfront storage fee for personal property contained in repossessed vehicles. These agents refused to return consumers' personal property until the consumers paid the fee. Reference Link

17:22 EDT Six Flags announces 10% workforce reduction - On October 13, Six Flags Entertainment committed to reduce its full-time workforce by approximately 240 employees, or 10%, as part of its transformation productivity initiatives. The company does not expect to incur material charges in connection with this workforce reduction. Affected employees are being offered severance pay in accordance with company policy or, if applicable, their employment agreements, as well as outplacement services. As a result, the company expects to record employee severance costs of approximately $1.5M in the third quarter and approximately $3M in the fourth quarter. The company will provide further details of the transformation productivity initiatives during its investor conference call on October 28.

17:16 EDT Laureate Education to transfer control of its operations in Honduras - Laureate Educatio announced that it has entered into a definitive agreement with Fundacion Nasser to transfer control of Fundaempresa, which manages Laureate's operations in Honduras - Universidad Tecnologica Centroamericana, including the operation of Centro Universitario Tecnologico. UNITEC and CEUTEC collectively enroll more than 23,000 students in technical, undergraduate and postgraduate programs in health, business, communications, engineering and information technology.

17:08 EDT Allscripts spikes up 25% to $10.35 after announcing $1.35B sale of CarePort

17:01 EDT Cummins raises quarterly cash dividend 3% to $1.35 from $1.311 per share - The dividend is payable on December 3 to shareholders of record on November 20.

17:00 EDT Scientific Games former chairman Perelman sells 1.96M shares of common stock - In a regulatory filing, Scientific Games discloses that its former executive chairman Ronald Perelman sold 1.96M shares of common stock on October 12th in a total transaction size of $55M. The holding represents about 18% of his total owned.

16:53 EDT Moderna CEO sells 19.3K shares of common stock - n a regulatory filing, Moderna discloses that its CEO Stephane Bancel sold 19.3K shares of common stock on October 9th in a total transaction size of $1.41M.

16:46 EDT American Water's Pennsylvania American Water buys wastewater assets for $17.5M - The company states: "Pennsylvania American Water, a subsidiary of American Water, announced that it has acquired the wastewater assets of the Borough of Kane Authority in McKean County for approximately $17.5M. The Authority's wastewater system serves nearly 2,100 customers in Kane Borough and Wetmore Township. The sale of the wastewater system is expected to allow the borough to eliminate its existing wastewater debt, fully fund borough pension plans, and invest in capital projects. Effective today, all four of Kane's employees, represented by AFSCME District Council 85, Local 3603, are now employees of Pennsylvania American Water."

16:41 EDT GameStop jumps after Senvest discloses 3.6M share stake - GameStop moved higher after Senvest Management disclosed a 5.54% stake in the company, which represents over 3.6M shares. The filing does not allow for activism. GameStop in after-hours trading is up 5%, or 62c, to $12.50. Senvest is an investment advisor founded by Richard Mashaal.

16:39 EDT Theratechnologies confirms issuance of patent covering Tesamorelin use - Theratechnologies announced that the United States Patent and Trademark Office, or USPTO, has issued U.S. Patent No. 10,799,562, which is directed to the treatment of Nonalcoholic Steatohepatitis, NASH, and/or Nonalcoholic Fatty Liver Disease, NAFLD, in patients using tesamorelin. This patent, which is scheduled to expire in 2040, stems from a patent application filed in March 2020 by Massachusetts General Hospital. Theratechnologies has an exclusive license with MGH to this patent.

16:34 EDT Bed Bath & Beyond to sell Christmas Tree Shops banner, other assets for $250M - Bed Bath & Beyond announced that it has entered into separate agreements to sell its Christmas Tree Shops retail banner, its institutional Linen Holdings business and a distribution center located in Florence, New Jersey. The company expects to generate a total of approximately $250M in aggregate from the monetization of these assets as it continues to optimize its portfolio, potentially including the sale of additional non-core assets. Bed Bath & Beyond has entered into a definitive agreement to sell Christmas Tree Shops to Handil Holdings. The purchase agreement includes all 80 brick-and-mortar Christmas Tree Shop locations and a Middleborough, Massachusetts distribution center. Handil Holdings expects to continue operating Christmas Tree Shops as a stand-alone retail brand. The companies have agreed to a transition service agreement, following the close of the transaction, to help ensure business continuity, particularly during the upcoming holiday season. The transaction is expected to close in November, subject to customary closing conditions. The company has also entered into a definitive agreement to sell its Linen Holdings business to The Linen Group, an affiliate of Lion Equity Partners. Linen Holdings will be merged with Riegel Linen, an existing Lion Equity portfolio company. Linen Holdings provides a broad selection of quality linen, terry, amenities, case goods and apparel to world-class businesses in the global hospitality and healthcare industries. The sale of Linen Holdings is expected to close in October, subject to customary closing conditions. Additionally, Bed Bath & Beyond has agreed to sell its distribution center in Florence, New Jersey to an institutional buyer. The sale continues the company's strategic program to streamline and modernize its distribution and omni-fulfillment capabilities as part of an ongoing review of real estate assets. Bed Bath & Beyond has signed a lease agreement with the buyer to continue operations and provide business continuity during a transition period. The Florence distribution center sale is expected to close in October, subject to customary closing conditions.

16:33 EDT Urban Outfitters announces management changes - Richard A. Hayne, CEO, of Urban Outfitters announced the following changes to the Company's management structure to better support URBN's future growth and strategic initiatives. Meg Hayne has been promoted to Co-President and will remain Chief Creative Officer. Meg will continue to manage the creative functions she currently oversees. In addition, our three large Brands and Sourcing will now report to Meg. Frank Conforti has been promoted to Co-President and COO. Frank will assume additional responsibility for URBN's Fulfillment & Logistics, Development, Legal, Talent and Human Resources Departments. Frank will continue to operate as CFO while the Company begins a search for his successor. Sheila Harrington has been promoted to CEO of the Free People Group.Hillary Super has been promoted to CEO of Anthropologie Group. Azeez Hayne has been promoted to Chief Administrative Officer and will remain General Counsel. Azeez will assume responsibility for URBN's Talent and Human Resources departments. Dave Hayne has been promoted to CTO and will remain the President of Nuuly. Dave will assume the additional responsibilities for URBN's IT department. Calvin Hollinger, COO of URBN, will be leaving the Company at the end of the month to pursue other opportunities.

16:23 EDT Terra Tech Corp CEO Matthew Morgan to step down, Michael Nahass to succeed - Terra Tech Corp announced it has appointed Michael Nahass as CEO. Nahass currently serves as Terra Tech's president, COO, secretary and treasurer as well as a director, and has been working at Terra Tech since its inception. Nahass was instrumental in the start-up operations of Terra Tech and he continues to manage the daily activities of Terra Tech. He takes over the position from Matthew Morgan, who has been CEO since February as he is stepping down to pursue other interests.

16:20 EDT Alaska Air expects October cash burn to be approximately $125M - Alaska Air said in a regulatory filing: "Our September cash burn was approximately $117M, which is higher than our August cash burn due to additional spend for incremental flying and increased debt service payments, offset by improved cash bookings. We expect October cash burn will be approximately $125M. This estimate excludes the $30M payment associated with furlough mitigation programs. It also assumes that demand levels improve slightly from September. Our cash burn measurement includes all operating cash receipts and disbursements, such as cash from bookings net of refunds, other operational cash in (loyalty, cargo, etc.), plus investment earnings, offset by all cash expenditures including normal debt service and capital expenditures. Cash burn excludes financing raised and payroll support funding. On September 28, 2020, Air Group closed an agreement with the U.S. Department of the Treasury to borrow up to $1.9B under the CARES Act loan program. We have drawn $135M to date, and remaining amounts are available to draw through March 31, 2021. As of October 9, 2020, Air Group had cash and short-term investments of approximately $3.6B, which excludes any cash and short-term investments held at McGee and ASA Assurance, Inc."

16:19 EDT Axis Capital estimates Q3 pretax loss $225M-$255M from catastrophe events - Axis Capital Holdings announced a preliminary net loss estimate in the range of $225M-$255M pre-tax, or $190M-$220M after-tax, for third quarter catastrophes and other events. This net loss estimate relates to Hurricanes Laura and Sally, the Midwest derecho, wildfires across the West Coast of the United States, the Beirut explosion and regional weather events in the United States, and is attributable to the company's insurance and reinsurance segments. The company also reaffirmed no change to its net loss estimate associated with first party coverages established for the COVID-19 pandemic in the first quarter of 2020. AXIS Capital reported accelerating improvements in pricing across most insurance lines of business. In addition, AXIS Capital noted improving trends in current accident year loss ratios excluding catastrophe and weather-related losses for its insurance and reinsurance businesses consistent with progress observed in the first half of 2020.

16:17 EDT New York Times reduces pension obligations by $235M - The New York Times Company announced that it has entered into an agreement with Massachusetts Mutual Life Insurance Company under which approximately $235M in pension obligations under The New York Times Companies Pension Plan will be transferred to MassMutual. This arrangement is part of the company's continued effort to manage the overall size and volatility of its pension plan obligations, and the administrative costs related thereto. Under the agreement, the pension plan will purchase from MassMutual a group annuity contract for approximately 1,850 retirees that will provide for an irrevocable commitment by MassMutual to make annuity payments to the affected retirees. As a result, the payment obligation and administration thereof for the affected retirees will be transferred to this highly rated insurance company with a long history of efficiently providing annuity benefits. The transfer will not change the amount of the monthly pension benefits received by the affected retirees. Affected retirees will soon receive information packages with further details. No action is required on their part. The company expects to finalize the transaction by early 2021. The purchase of the group annuity contract will be funded through existing pension plan assets. As a result of the transaction, the company expects to recognize a non-cash pension settlement charge of approximately $80M-$85M before tax in the fourth quarter of 2020. This charge represents the acceleration of deferred charges currently accrued in accumulated other comprehensive income.

16:16 EDT Dover's Pole/Zero awarded $24M contract by U.S. Navy - Pole/Zero, part of Microwave Products Group and Dover, has been awarded a $24.2M delivery order from the U.S. Navy as part of what initially was a $66M indefinite delivery, indefinite quantity contract that was originally awarded back in 2018. The new delivery order includes antenna interface units and mounting trays, technical data, and post-delivery support for the P-8A Poseidon Lot 11 full-rate production aircraft in support of the U.S. Navy and its allies located in New Zealand and the Republic of Korea. Additionally, spare units ordered will be distributed throughout the P-8A end customer locations. Manufacturing will be performed at Pole/Zero's world-class facility located in West Chester, Ohio, and deliveries will be completed by March 2023.

16:12 EDT Loop Industries says Hindenburg Research report contained 'factual inaccuracies' - Loop Industries commented on the report published by Hindenburg Research this morning. The company said the report contained factual inaccuracies. Per the Hindenburg report, Hindenburg holds a short position in Loop Industries stock. Loop said, "Hindenburg Research has not engaged with Loop directly nor does Loop Industries believe Hindenburg Research has done the required due diligence for this report. The claims it makes are either unfounded, incorrect, or based on the first iteration of Loop's technology, known as Gen 1, which was in use between 2014 and 2017. In 2017, Loop reinvented its process and developed its Gen 2 technology, which is at the core of Loop's commercialization projects. Loop's focus remains on commercializing its technology to meet growing global demand for infinitely recyclable PET plastic and polyester fiber made from 100% recycled content."

16:07 EDT ICF International awarded $9M task order by U.S. DOL - ICF was recently awarded a $9M re-compete task order for research support services under its blanket purchase agreement with the U.S. Department of Labor, or DOL, Bureau of International Labor Affairs, or ILAB. The five-year task order includes a one-year base and four one-year option periods. Under this contract, ICF will continue to provide research and publication support for ILAB's production of congressional and executive order reports on child labor, forced labor and human trafficking.

16:06 EDT Hostess Brands names Jerry Kaminiski chairman of the board - Hostess Brands announced that Dean Metropoulos has notified the company that he will resign from the company's board of directors at the end of 2020 in order to pursue other commitments. Current independent director Jerry Kaminski has been appointed Chairman of the Board, effective immediately. "Transforming Hostess into one of the premier branded CPG companies in the industry, initially as CEO and recently as Chairman, has been very successful," said Mr. Metropoulos. "Over the past two years, the management team has built a strong foundation and is positioned for continued industry leading revenue growth at industry leading margins, following the successful Voortman acquisition to build value. Hostess' best years are ahead and I am very confident the Company will continue to thrive, as it continues to establish new platforms for incremental growth, both organic and through acquisitions." The Board of Directors has appointed current independent director Jerry Kaminski as its new Chairman. Mr. Kaminski has served on Hostess' Board of Directors since November 2016 and is currently Executive Vice President and Chief Operating Officer at Land O'Lakes Inc., where he has served in various roles since 2012.

16:02 EDT Simpson Manufacturing names Michael Olosky as COO, succeeding Ricardo Arevalo - Simpson Manufacturing announced Michael Olosky will be joining the company as COO, effective November 30th. Olosky succeeds Simpson's former COO Ricardo Arevalo, who retired in February after 20 years of service to the company. Prior to joining Simpson, Olosky spent over 22 years in numerous leadership positions at Henkel, a global chemical and consumer goods company.

15:39 EDT Comcast announces Xfinity Mobile expanding 5G coverage nationwide - Comcast announced Xfinity Mobile is expanding its 5G coverage nationwide across the U.S. Starting October 14, Xfinity Mobile's nationwide 5G network will be available on all Xfinity Mobile data options and can be accessed by all 5G-enabled devices in the Xfinity Mobile portfolio, the company announced.

15:03 EDT Hyatt, Genting announce plans for new hotel at Resorts World Casino New York - Hyatt Hotels (H) and Genting Americas announced plans for a new hotel located at Resorts World Casino New York City, or RWNYC. Hyatt Regency JFK at Resorts World New York is scheduled to open in the first quarter of 2021 and will be "an eight-story 400-room four-star hotel with residential-inspired guestrooms and premium suites with energizing design and insightful in-room technology," the companies stated. Pete Sears, Americas group president, Hyatt, added: "This new hotel will be a testament to Hyatt's commitment to growing with intent in markets that matter most to our loyal members and global guests."

14:41 EDT Eli Lilly down 3% after COVID-19 antibody trial paused for safety concerns - In afternoon trading, shares of Eli Lilly are down $4.34, or 2.8%, to $150.15.

14:18 EDT Kirkland Lake Gold reports Q3 production up 37%, raises quarterly dividend 50% - Earlier in the day, Kirkland Lake Gold announced production results for the third quarter and first nine months of 2020. Q3 2020 production totaled 339,584 ounces, an increase of 91,184 ounces or 37% from 248,400 ounces for the third quarter of 2019. For YTD 2020, the Company produced 1,000,218 ounces, 305,345 ounces or 44% higher than the first nine months of 2019. The company also announced today a 50% increase in the quarterly dividend, to 18.75c per share, effectiveQ4. The company's cash position increased 58% during Q3 2020 to $848M at September 30, 2020 with no debt. The increase in cash reflected proceeds from the sale of 331,959 ounces of gold during Q3 2020 at an average realized price of $1,907 per ounce. Also contributing to the growth in cash during the quarter were proceeds of $109.1M from the sale of the company's 32.6M shares of Osisko Mining Inc. and $75M received from Newmont Canada FN Holdings through a strategic alliance agreement.

14:11 EDT Apple announces iPhone 12 and iPhone 12 mini - Apple unveiled iPhone 12 and iPhone 12 mini with 5G technology, "ushering in a new era for the world's best smartphone." iPhone 12 models feature edge-to-edge Super Retina XDR displays and a new Ceramic Shield front cover, "providing the biggest jump in durability ever on iPhone," according to Apple's press release. The Apple-designed A14 Bionic "powers every experience on iPhone 12, and coupled with an advanced dual-camera system, delivers meaningful new computational photography features and the highest quality video in a smartphone," Apple added. iPhone 12 models also introduce MagSafe, offering high-powered wireless charging and an all-new ecosystem of accessories, the company said. iPhone 12 and iPhone 12 mini will be available in 64GB, 128GB, and 256GB models in blue, green, black, white, and (PRODUCT)RED, starting at $799 and $699, respectively. Pre-orders for iPhone 12 begin Friday, October 16, with availability beginning Friday, October 23. iPhone 12 mini will be available for pre-order beginning Friday, November 6, and in stores beginning Friday, November 13.

14:10 EDT Apple unveils iPhone 12 Pro, iPhone 12 Pro Max with 5G - Apple announced iPhone 12 Pro and iPhone 12 Pro Max, introducing a powerful 5G experience and advanced technologies that push the boundaries of innovation for users who want the most out of iPhone. iPhone 12 Pro models feature a new design and edge-to-edge Super Retina XDR displays, the largest ever on iPhone, protected by the all-new Ceramic Shield front cover, which provides the biggest jump in durability ever on iPhone. The Apple-designed A14 Bionic chip, the fastest chip in a smartphone, powers impressive computational photography features including the all-new Apple ProRAW for more creative control in photos, and enables the first end-to-end Dolby Vision video experience, up to 60 fps. The reimagined pro camera systems include an expansive Ultra Wide camera, a Telephoto camera with an even longer focal length on iPhone 12 Pro Max, and new Wide cameras to capture beautiful professional-quality images and video in bright and low-light environments. iPhone 12 Pro models also introduce a new LiDAR Scanner for immersive augmented reality experiences and MagSafe, which offers high-powered wireless charging and an all-new ecosystem of accessories that easily attach to iPhone. iPhone 12 Pro and iPhone 12 Pro Max will be available in four stainless steel finishes, including graphite, silver, gold, and pacific blue. Pre-orders for iPhone 12 Pro begin Friday, October 16, with availability beginning Friday, October 23. iPhone 12 Pro Max will be available for pre-order Friday, November 6, and in stores beginning Friday, November 13. iPhone 12 Pro and iPhone 12 Pro Max will be available in 128GB, 256GB, and 512GB models in graphite, silver, gold, and pacific blue starting at $999 and $1,099, respectively. Customers can also get iPhone 12 Pro for $29.12 a month or $699 with trade-in and iPhone 12 Pro Max for $30.37 a month or $729 with trade-in from apple.com, in the Apple Store app, and at Apple Store locations. iPhone 12 Pro and iPhone 12 Pro Max are also available through Apple Authorized Resellers and select carriers.

14:06 EDT Apple says iPhone 12 Pro will start at $999, iPhone 12 Pro Max at $1,099 - This comment was taken from the Apple Event.

14:01 EDT Verizon expands availability of 5G Ultra Wideband service to 55 U.S. cities - Verizon (VZ) announced that it "is driving 5G forward" by deploying its 5G Ultra Wideband service, built on mmWave spectrum, in 19 additional U.S. cities, 19 stadiums and six airports, and "doubling download speeds on the fastest 5G service in the world - reaching 4 Gbps peak speeds in some locations." Verizon noted that its expansion means availability of its 5G Ultra Wideband service is now available in 55 cities, 43 stadiums and arenas, and seven airports. "Verizon is also turning on 5G Nationwide service for more than 200 million people nationwide and developing exciting new solutions with partners who seek the same level of performance and operational excellence including the National Football League, The New York Times, and Riot Games. Verizon will be offering the first iPhone with 5G, and introducing powerful new capabilities to customers with Verizon's 5G Ultra Wideband and Nationwide networks," the company added, timing its press release to coincide with Apple's (AAPL) ongoing iPhone launch event.

13:45 EDT Apple says iPhone 12 will start at $799, iPhone 12 mini will start at $699 - This comment was taken from the Apple Event.

13:37 EDT Apple introduces MagSafe for iPhone, to improve wireless charging

13:31 EDT BioHiTech Global receives additional food waste digester order valued at $300K - BioHiTech Global announced it has received an additional purchase order for its Revolution Series food waste digesters from Princess Cruises, valued at approximately $300,000. BioHiTech expects to deliver these digesters for installation on Princess Cruises' newest ship, the Enchanted Princess during the fourth quarter of 2020. "We continue to see sales momentum for our digesters in the cruise industry and this latest order from Princess Cruises represents their consistent commitment to sustainability and environmental stewardship," said Frank E. Celli, CEO of BioHiTech Global.

13:21 EDT Apple introduces iPhone 12, which features 5G support - This comment was taken from the Apple Event.

13:17 EDT Apple introduces HomePod mini, available for $99 - Apple unveiled HomePod mini, which it calls "the newest addition to the HomePod family that delivers impressive sound, the intelligence of Siri to get things done, and a smart home experience that offers comfort and convenience without complexity. Apple added: "At just 3.3 inches tall, HomePod mini is packed with innovative technologies and advanced software that together enable computational audio to deliver breakthrough audio quality wherever it is placed." HomePod mini will be available in white and space gray for $99 in the U.S. from apple.com, in the Apple Store app, Apple Store locations, and through Apple Authorized Resellers and select carriers. Customers in Australia, Canada, France, Germany, Hong Kong, India, Japan, Spain, the UK, and the U.S. are able to order HomePod mini beginning at 5 a.m. PST on Friday, November 6, with availability beginning the week of November 16. HomePod mini will be available in China, Mexico, and Taiwan later this year, Apple said.

13:15 EDT Apple CEO Tim Cook announces bringing 5G to iPhone - This comment was taken from the Apple Event.

13:09 EDT CorVel Chairman Gordon Clemons sold over $268K in company shares - CorVel Chairman Gordon Clemons sold 3,000 shares of stock between October 8 and October 12 for $89.36 per share for a total transaction of $268,082.

12:35 EDT Ontrak rises after announcing launch of Ontrak-CI program - Shares of Ontrak (OTRK) are up nearly 6% 6o $66.00 in afternoon trading after the company announced this morning the launch of its Ontrak-CI solution for Medicare Advantage members of a "National Health Plan" in a simultaneous 13-state expansion. Subsequent to a three-year contract awarded to Ontrak in June 2020, the company is now enrolling Medicare Advantage members in 13 additional states, Ontrak stated, without identifying the partner company in its press release. Terren Peizer, Chairman and CEO of Ontrak, stated, "This is the second national health plan to roll out our Ontrak program across their national book of business. While the expansion of business with the nation's largest health plans is rarely a rapid process, we were able to establish a trusted partnership with this health plan during the additional 9 months that it took to overcome some of their 2019 enterprise reorganization and 2020 data integration challenges. With anxiety approaching record highs nationwide, particularly among the Medicare population, we look forward to providing critical behavioral healthcare to these members and to leveraging our strong ROI and clinical outcomes for this health plan into their other books of business."

12:29 EDT Chart Industries signs strategic commercial hydrogen MOU with McPhy - Chart Industries announced of its firm undertaking to subscribe to the share capital increase initiated today by McPhy for an amount of 30M euros, which will result in approximately c. 4.3% of the capital of McPhy, post completion of an anticipated 150M euros capital offering. McPhy specializes in zero-carbon hydrogen production and distribution equipment.In conjunction with the strategic investment, Chart and McPhy also executed a commercial Memorandum of Understanding. The MoU between McPhy and Chart is intended to set the pace of commercial collaboration to stimulate new hydrogen demand for the parties' respective equipment and solutions globally, by identifying new customers and projects. Chart and McPhy will also work on studying options to scale up projects for production, storage, transport and fueling in all addressable markets. Included at the end of this release is a supplemental presentation that describes the agreement and expanded addressable market for Chart's hydrogen business by 2023 to $1.1B.

12:00 EDT Royal Caribbean falls -10.5% - Royal Caribbean is down -10.5%, or -$7.34 to $62.49.

12:00 EDT Global Ship Lease falls -11.0% - Global Ship Lease is down -11.0%, or -81c to $6.57.

12:00 EDT ReneSola rises 15.5% - ReneSola is up 15.5%, or 53c to $3.92.

11:32 EDT Chart acquires Worthington's cryogenic trailer, hydrogen trailer business - Chart Industries (GTLS) completed the acquisition of the Theodore, Alabama cryogenic trailer and hydrogen trailer assets of Worthington Industries (WOR). This acquisition includes ownership of the Theodore, Alabama manufacturing site, all trailer-related intellectual property, manufacturing capabilities, equipment and repair backlog. The facility has approximately 300,000 square feet under roof adjacent to the Port of Mobile, and the associated employees will join the Chart team. This acquisition will produce strong synergies by combining Chart's deep knowledge of cryogenics and liquid hydrogen storage and handling with the Theodore operation's expertise and experience in the packaging and assembly of liquid hydrogen trailers. The addition of the trailer business to Chart's hydrogen equipment and solution offering expands our mobile equipment to larger sized transports and brings another location already certified by significant hydrogen customers. Expected Chart hydrogen-related revenue from this facility in 2021 is $15M to $20M with upside potential to $30M in 2021.

11:05 EDT Moderna initiaties rolling submission to Health Canada for mRNA vaccine - Moderna announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Company's vaccine candidate against COVID-19. This initiation follows positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in healthy adults and older adults published in the New England Journal of Medicine. The rolling submission has been accepted under the Canadian Minister of Health's Interim Order, which permits companies to submit safety and efficacy data and information as they become available. This rolling review process allows Health Canada to begin its assessment using the information submitted by the applicant and accept new evidence as it becomes available until the application is deemed complete. This process can reduce time to authorization for these important new drugs while maintaining appropriate standards of safety, efficacy, and quality. Health Canada will not make a decision to authorize any vaccine being considered under rolling review until it has received all necessary evidence to support its safety and efficacy. Following the authorization of any vaccine submission, Health Canada will publish the evidence used in making its decision for transparency. On September 22, the Canadian Government increased its confirmed order commitment to 20 million doses of mRNA-1273. Moderna remains on track to be able to deliver up to 56 million doses of its COVID-19 vaccine to help protect Canadians beginning in 2021. The Canadian vaccine supply will be sourced from Moderna's European production capacity with its strategic manufacturing partner Lonza of Switzerland, and ROVI of Spain for fill-finish services. The Phase 1 interim analysis showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2. In the 18-55 age group, neutralizing antibody titers were observed in 100% of evaluated participants and at the 100 microgram dose level selected for Phase 3, the geometric mean titers were above those seen in convalescent sera. Similarly, mRNA-1273 induced consistently high levels of pseudovirus neutralization antibody titers in all participants in the 56-70 and 71+ age groups. In addition, vaccination with mRNA-1273 elicited Th1-biased CD4 T cell responses in all age groups. mRNA-1273 is currently being studied in a Phase 3 randomized, 1:1 placebo-controlled trial of 30,000 participants at the 100 microgram dose level in the U.S. As of Friday, October 9, the Phase 3 COVE study has enrolled approximately 28,618 participants with 22,194 having received their second vaccination.

11:02 EDT Humanigen says NIH launches ACTIV-5 "Big Effect Trial" with lenzilumab - Humanigen announced that the National Institute of Allergy and Infectious Diseases, part of the U.S. National Institutes of Health, launched its ACTIV-5 "Big Effect Trial", designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and, therefore, merit advancement into larger clinical trials. ACTIV-5/BET, which will enroll at as many as 40 US sites, will evaluate lenzilumab with remdesivir, compared to placebo and remdesivir, in hospitalized COVID-19 patients with approximately 100 patients assigned to each study arm. Humanigen is providing lenzilumab for the study, which is fully funded by NIH. ACTIV-5/BET is being conducted in collaboration with the NIH's public-private partnership Accelerating COVID-19 Therapeutic Innovations and Vaccines program. The ACTIV partnership has evaluated approximately 400 therapeutic agents with a potential application for COVID-19 and developed a collaborative framework for prioritizing the most promising candidates, streamlining clinical trials, coordinating regulatory processes, and leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics. To date, ACTIV has designed five adaptive master protocols for ACTIV clinical trials, and selected numerous NIH-supported networks to launch these clinical trials to test prioritized therapeutic candidates.

10:43 EDT Citi watching for when to re-enter card acquisition efforts

10:32 EDT RedHill Biopharma announces pacts to expand COVID-19 candidate manufacturing - RedHill Biopharma announced collaborations with two specialist pharmaceutical manufacturers in Europe and Canada to ramp-up manufacturing of opaganib, currently in "swiftly progressing" global Phase 2/3 and U.S. Phase 2 studies for severe COVID-19 pneumonia, to support potential emergency use applications and subsequent demand. "In light of the rapid progress of our Phase 2/3 COVID-19 development program with opaganib, we are expanding manufacturing capabilities and capacity for opaganib with trusted and high-quality partners, to meet likely demand ahead of potential global emergency use applications," said Reza Fathi, RedHill's Senior VP, R&D. "The company is in discussions with U.S. government agencies around potential funding to support the rapid advancement of opaganib toward potential emergency use applications and manufacturing scale-up," RedHill added.

10:30 EDT Citi doesn't see material reserve builds, release in Q4

10:26 EDT Citi sees continued pressure in Consumer in Q4

10:24 EDT Delta CFO says on track to end year with more than $16B in liquidity - Delta CFO Paul Jacobson said on the company's earnings call that Delta is on track to end the year with more than $16B in liquidity and adjusted net debt of approximately $19B.

10:15 EDT Citi sees reserve releases coming down in 2021 - Sees drop in allowance for loan losses in 2021.

10:11 EDT Citi sees 'somewhat slower' recovery in unemployment, GDP through 2022

10:07 EDT Eos Energy enters partnership with Babcock & Wilcox to supply batteries - Eos Energy Storage announced that it has entered into an agreement with Babcock & Wilcox (BW) to be the exclusive battery supplier for B&W's global customer base of industrial, utility and power companies. The agreement will also enable Eos to leverage B&W's global experience as a leader in providing renewable energy and environmental technologies, services and solutions to utility and industrial customers. As previously announced, B. Riley Principal Merger Corp. II and Eos have entered into a definitive merger agreement for a business combination that would result in Eos becoming a publicly listed company. Upon closing of the transaction, the combined company will be renamed Eos Energy Enterprises and intends to list its shares of common stock on Nasdaq under the ticker symbol "EOSE". B&W will market, sell and service Eos' signature product, the Znyth zinc battery system, which is optimized for the critical longer duration stationary storage market and ideal for grid congestion and renewable power applications. Under the agreement, B&W subsidiary Babcock & Wilcox Construction Co., LLC, will be Eos' exclusive preferred installation provider for the technology in the United States and Canada.

10:07 EDT Delta CEO says 'no documented cases' of COVID-19 transmission on its flights - Delta Air Lines CEO Ed Bastian is speaking on the company's Q3 earnings call.

10:02 EDT Rite Aid announces paid time off, flexible hour policy for Election Day - Rite Aid announced a new paid time off and flexible hour policy for associates on Election Day, Tuesday, November 3, to ensure that all Rite Aid associates have time to vote and make their voices heard. For hourly associates scheduled to work on Election Day, Rite Aid is providing up to two hours of paid time off to guarantee that every associate has time to cast a ballot, without the worry of missing work obligations. Rite Aid is the first drugstore chain to announce a paid time off program for hourly associates. Additionally, the company is minimizing barriers to voting for corporate employees by instituting a policy to limit the hours for meetings scheduled and provide flexible hours on Election Day.

10:00 EDT ReneSola rises 8.0% - ReneSola is up 8.0%, or 27c to $3.66.

10:00 EDT iHuman rises 19.4% - iHuman is up 19.4%, or $4.36 to $26.80.

09:51 EDT Johnson & Johnson says 'bullish' on greater than 70% COVID-19 shot efficacy

09:47 EDT Ternium falls -11.5% - Ternium is down -11.5%, or -$2.27 to $17.55.

09:47 EDT Direxion Daily Junior Gold Miners Index Bear 3x Shares rises 5.2% - Direxion Daily Junior Gold Miners Index Bear 3x Shares is up 5.2%, or 50c to $10.20.

09:47 EDT Ethan Allen rises 16.8% - Ethan Allen is up 16.8%, or $2.63 to $18.26.

09:44 EDT MoneyGram reports 161% y/y cross-border transaction growth for MoneyGram Online - MoneyGram International announced another month of digital growth in September. The Company delivered 161% year-over-year cross-border transaction growth for MoneyGram Online, its direct-to-consumer digital business, marking its ninth consecutive month of triple-digit growth. This growth continues to be driven by strong consumer demand for the Company's leading mobile app and a full suite of leading digital capabilities available in over 75 countries. As a result of the pandemic starting to rapidly spread in early 2020, numerous organizations projected annual remittance flows would decline materially. In contrast to these predictions, MoneyGram has reported a sizable uptick in global money transfers, particularly in its direct-to-consumer digital business as a result of the Company's ongoing digital transformation to build the world's best modern, mobile, and API-driven money transfer platform.

09:42 EDT Verisk Analytics, Ford collaborate to offer telematics data to insurers - Verisk (VRSK) announced that Ford Motor Company (F) has joined the Verisk Data Exchange. Owners of eligible Ford and Lincoln vehicles will soon have easy access to usage-based insurance programs from the many U.S. auto insurers that connect to the Exchange-including three of the ten largest U.S. carriers.

09:40 EDT Enlivex: Israeli Ministry of Health authorizes initiation of Phase II trial - Enlivex Therapeutics reported that the Israeli Ministry of Health authorized the initiation of a proposed investigator-initiated Phase II clinical trial evaluating AllocetraTM in severe and critical COVID-19 patients. The planned COVID-19 study is a multi-center investigator-initiated, Phase II clinical trial. The trial is expected to recruit up to twenty-four COVID-19 patients in severe or critical condition, and is designed to assess Allocetra in combination with standard of care treatment. The trial plans to evaluate safety, tolerability, cytokine profile and efficacy parameters. Enlivex recently reported positive top-line results of a previously announced Phase Ib investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe and critical condition in Hadassah Hospital, one of the largest hospitals in Israel. Enlivex was scheduled to provide the Israeli Ministry of Health with a full summary of the completed Phase Ib study following a 28-day observational period for each of the five patients treated in that study, which period is scheduled to lapse in late October. However, based on the positive Phase Ib top-line results and the release from the hospital of all patients treated in that study, after having tested negative for COVID-19, the Israeli Ministry of Health requested expedited submission by Enlivex of its COVID-19 Allocetra Phase Ib clinical trial summary prior to the completion of the full 28-day period for the last patient in order to expedite the regulatory review process. The Phase Ib clinical trial included five COVID-19 patients, three in severe condition and two in critical condition. All five patients completely recovered from their respective severe/critical condition and were released from the hospital after an average of 5 day and 9 days, following administration of AllocetraTM, at which time they were all COVID-19 PCR negative. There were no reported severe adverse events relating to the administration of AllocetraTM in the patients, and the therapy was well-tolerated.

09:30 EDT Endra Life Sciences announces issuance of two patents - Endra Life Sciences has been issued international registration certificates, patents, DM/210628 and DM/210629 by the World Intellectual Property Organization, WIPO. These patents are for proprietary designs of ENDRA's Fatty Liver Imaging Probe and protect ENDRA's "Thermoacoustic Imaging Probe" and "Thermoacoustic Imaging Probe With Outdents. "We are committed to protecting our intellectual property in key global markets and are pleased to receive these two new patents as we begin to commercialize our proprietary TAEUS technology in areas of high unmet clinical need, such as Non-Alcoholic Fatty Liver Disease, NAFLD.

09:26 EDT Movado and eShopWorld in partnership pact amid COVID-19 - Movado Group and eShopWorld, ESW, announced that they have launched a partnership to provide Movado and MVMT shoppers in markets across the globe with a localized, familiar online shopping experience. ESW simplifies each aspect of the cross-border e-commerce process by removing the challenges brands encounter when trying to sell and ship product internationally. The partnership will help prepare Movado and MVMT to meet early holiday demand due to the effects of COVID-19. "Movado timepieces, with their iconic single dot on the dial, are known worldwide for their innovative design, craftsmanship and quality," said Tommy Kelly, CEO of ESW. "Shoppers know they can expect a luxurious experience at every step of the shopping journey with Movado, and we're excited to partner with the company ahead of the holidays to ensure that the experience is as seamless, simple and familiar as possible for them, wherever they reside."

09:18 EDT Invesco launches QQQ Innovation Suite in partnership with Nasdaq - Invesco (IVZ) announced the launch of the Invesco QQQ Innovation Suite, which offers investors access to the NASDAQ-100 Index (NDAQ) and NASDAQ Next Generation 100 Index through a variety of investment structures and exposures. The Invesco QQQ Innovation Suite represents the next step in the continued democratization of investing. It advances the growing concept that innovation in investing continues to drive benefits to the end investor, not just through direct cost-savings, but in the personalization of the investment model. The Invesco QQQ Innovation Suite meets all clients' implementation preferences, providing every type of investor a simple way to invest in ingenuity and innovation.

09:18 EDT Airgain selected by Getac to provide antennas for rugged devices - Airgain announced that it has been chosen by Getac, a provider of rugged laptops, notebooks and tablets as their strategic antenna partner for rugged devices. Airgain's antenna solutions have been custom designed for Getac's pre-configured rugged devices, optimizing connectivity for data transmission.

09:16 EDT Delta CEO says early advanced look for Thanksgiving and Christmas 'encouraging' - Delta Air Lines CEO Ed Bastian says "consumers are feeling really safe with travel" and the airlines' early advanced look for Thanksgiving and Christmas has been "encouraging." Bastian made the comments during an interview on CNBC following the company's release of its earnings report earlier this morning.

09:15 EDT AMC says cash will be largely depleted by end of 2020, early 2021 - AMC Entertainment disclosed this morning that "given the reduced movie slate for the fourth quarter, in the absence of significant increases in attendance from current levels or incremental sources of liquidity, at the existing cash burn rate, the Company anticipates that existing cash resources would be largely depleted by the end of 2020 or early 2021. Thereafter, to meet its obligations as they become due, the Company will require additional sources of liquidity or increases in attendance levels. The required amounts of additional liquidity are expected to be material." AMC continues to explore potential sources of additional liquidity, including additional debt and equity financing, further renegotiations with landlords regarding its lease payments, potential asset sales, joint-venture or other arrangements with existing business partners, and minority investments in capital stock. "There is a significant risk that these potential sources of liquidity will not be realized or that they will be insufficient to generate the material amounts of additional liquidity that would be required until the Company is able to achieve more normalized levels of operating revenues,: AMC said in a regulatory filing. "It is very difficult to estimate our liquidity requirements and future cash burn rates, and depending on the assumptions used regarding the timing and ability to achieve more normalized levels of operating revenue, the estimates of amounts of required liquidity vary significantly," it added. AMC shares are down 15c to $3.93 in premarket trading.

09:13 EDT Johnson & Johnson says planning for 'above market growth' in 2021

09:13 EDT Oshkosh awarded contract for 322 VLV for Belgium Defence Forces - Oshkosh announced that the Belgium Ministry of Defence has awarded Oshkosh Defense a contract for 322 Oshkosh Defense Command and Liaison Vehicles, or CLV, for the Belgium Defence Forces. The Belgian CLV is the proven Joint Light Tactical Vehicle, or JLTV, platform from Oshkosh equipped with Belgian communication systems. The JLTV is currently used by the U.S. military.

09:11 EDT AMC says competitor closings may exacerbate reduced film openings - AMC Entertainment said this morning in a regulatory filing: "Major movie releases that were previously scheduled to be released in the fourth quarter have either been rescheduled for 2021 or slated for direct to streaming in lieu of a theatrical release, leaving a reduced slate of movie releases for the remainder of the year, and release dates may continue to move. Certain competitors have decided to temporarily reclose their theatres in light of the ongoing pandemic and the reduced slate of movie releases, which may further exacerbate the trend described above. In response to the current low attendance levels, the Company has made adjustments to theatre operating hours to align screen availability and associated theatre operating costs with attendance levels for each theatre."

09:11 EDT AT&T receives $1.1B in cash from CME acquisition - Czech investment firm PPF Group completed its acquisition of Central European Media Enterprises, or CME. With the transaction closed, AT&T, which was the largest shareholder in CME, received $1.1B in cash and no longer backstops approximately $575M in CME debt. AT&T acquired its stake in CME with the acquisition of Time Warner, now WarnerMedia, in 2018. The company said the sale is consistent with AT&T's ongoing efforts to monetize non-core assets to drive incremental shareholder value. The company plans to continue to focus on lowering its net debt.

09:09 EDT Aesthetic Medical announces $6M share repurchase program - Aesthetic Medical International Holdings announced that its board of directors has authorized a share repurchase program under which the Company may repurchase up to $6M worth of its American depositary shares over the next 12-month period, effective until October 12, 2021, pursuant and subject to applicable laws and the Company's securities trading policy. All factors, including, but not limited to, trading price, trading volume and general market conditions, along with the Company's working capital requirements and general business conditions shall be taken into account when determining the timing, volume and conditions of the share repurchases under the share repurchase program.

09:08 EDT Dimon hopes JPMorgan can buy back stock before stock goes higher

09:07 EDT Comtech unit gets additional $5.9M on U.S. Army contract - Comtech Telecommunication announced that its Mission-Critical Technologies group, which is part of Comtech's Government Solutions segment, received additional funding of $5.9M on its previously announced contract to provide the U.S. Army with global field support services for military satellite communication , SATCOM, terminals around the world. The contract has been funded $41.1M to date. "Comtech is honored to support our warfighters with high quality and responsive field support services around the world," said Fred Kornberg, Chairman of the Board and Chief Executive Officer of Comtech Telecommunications Corp.

09:06 EDT SurveyMonkey launches GetFeedback platform - SurveyMonkey launched its new customer experience solution, the GetFeedback platform. Announced at SurveyMonkey's inaugural customer experience event, the CX Impact Summit, the multi-channel offering is an easy-to-deploy, cost-efficient CX solution that helps organizations set up their CX program within days-not months-to quickly understand and act on customer insights. This agile approach to customer experience allows organizations to deliver meaningful experiences that increase customer satisfaction and loyalty. With the GetFeedback platform, companies will spend less time configuring complicated CX technology and more time focusing on what matters most: nurturing customer relationships.

09:04 EDT Lineage Cell Therapeutics announces preliminary results from study of VAC2 - Lineage Cell Therapeutics announced "encouraging preliminary results from an ongoing Phase 1 clinical study of VAC2 in non-small cell lung cancer,NSCLC. VAC2 demonstrated remarkably potent induction of immune responses in all patients dosed to date, with high levels of peripheral antigen-specific immunogenicity observed at multiple time points and confirmed by multimer staining. On the basis of these findings, and following completion of the ongoing VAC2 clinical study in NSCLC, Lineage will seek to evaluate VAC2 in combination with therapies considered biologically complementary to VAC2, such as chemotherapy and the immune cell protectant properties offered by anti-PD1 immunotherapy., " noted the company. Based on review of all available data, the therapy was safe and well tolerated in all patients. While the safety profile was expected, the immunogenicity data are remarkable and highly provocative," stated Christian Ottensmeier, MD, PhD, FRCP, Professor of Experimental Medicine at the University of Southampton and Chief Investigator on the VAC2 clinical study. "Antigen-reactive pentamer staining data induced by VAC2 suggest that the vaccine is highly potent, inducing significantly higher levels of antigen-specific T cells, compared with that invoked by alternative vaccine approaches, such as DNA- and RNA-based vaccines. From my perspective as an immuno-oncologist these data support rapid phase II testing, focused on clinical benefit."

09:03 EDT eXp World Holdings expands residential real estate network to sSouth Africa - eXp World Holdings announced the expansion of its brokerage model into South Africa under the eXp South Africa banner. The addition of residential and commercial brokerage operations in South Africa represents the fourth international expansion for the U.S.-headquartered company. In addition to its robust U.S. presence, eXp Realty also operates in Canada, the United Kingdom and Australia, with more than 35,000 agents in its global network.

09:02 EDT Panhandle Oil & Gas changed name to PHX Minerals - Panhandle announced that it has officially changed its name to PHX Minerals effective October 8. In conjunction with its name change the Company has also unveiled a new logo. The Company's ticker will remain "PHX" on the NYSE.

09:01 EDT Auris Medical initiates Part B of TRAVERS Phase 2 study of AM-125 - Auris Medical Holding announced that the first patient has been randomized in Part B of its "TRAVERS" Phase 2 trial of AM-125 in acute vertigo. This follows the positive read-out from the interim analysis on Part A of the study in early September 2020, the completion of enrollment into the oral treatment group, and the receipt of regulatory clearance for Part B in the first three of the participating study countries. In Part B of the TRAVERS trial, the Company will enroll 72 patients who suffer from acute vertigo following neurosurgery. They will be randomized to receive either 10 or 20 mg of intranasal betahistine or a placebo three times daily for four weeks. The improvement in the "Standing on Foam" test from baseline to Day 14 will be the primary efficacy endpoint; the improvement in the "Tandem Romberg" test to Day 42 will be the key secondary efficacy endpoint. The two tests measure how long patients are able to maintain balance on a foam mat or with the two feet aligned one after the other, respectively, while they have their eyes closed. As the Company remained blinded to treatment allocation during the interim analysis, the corresponding data from Part A will be pooled with those from Part B. The Company expects to complete enrollment into Part B of the TRAVERS trial by the end of the first quarter 2021, provided that the Covid-19 pandemic does not cause further restrictions on patient enrollment.

08:57 EDT JPMorgan: Reserves prepared for 'relative adverse case'

08:55 EDT Delta Air Lines down 4% to $31.40 after Q3 adjusted results miss estimates

08:53 EDT On Deck Capital trading halted, news dissemination

08:53 EDT JPMorgan doesn't see much higher chargeoffs until 2H21

08:52 EDT Motus GI Holdings hosting KOL call on improving endoscopy outcomes - Motus GI Holdings announced that it will host a key opinion leader call on improving inpatient endoscopy outcomes with the Pure-Vu system on Friday, October 16, 2020. The webinar will feature a presentation by KOL Seth Gross, MD, NYU Langone, who will discuss: The unmet needs and challenges associated inpatient colonoscopy; The benefits to patients in reducing time in the hospital, especially during the COVID-19 pandemic; Mitigating increasing costs to hospitals due to delayed / incomplete procedures Dr. Gross will be available to answer questions following the formal presentation. Motus GI's management team will also provide an update on the Pure-Vu System, a U.S. FDA cleared medical device indicated to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure. The device integrates with standard and slim colonoscopes to enable safe and rapid cleansing during the procedure while preserving established procedural workflow and techniques. Within the last year, the Company initiated its commercial launch of the Pure-Vu System in the U.S. with an initial focus on inpatient colonoscopy. The system is currently in more than 20 major U.S. hospitals, including NYU Langone Medical Center, Cleveland Clinic, UC-Irvine Health, UCLA Health, University of Texas, Memorial Hermann and Geisinger Medical Center.

08:51 EDT JPMorgan sees 2021 NII 'under pressure' vs. 2020

08:49 EDT JPMorgan branch expansion continuing

08:47 EDT Agenus appoints Susan Hirsch to board of directors - Agenus announced the election of Ms. Susan Hirsch to Agenus' Board of Directors. Susan has over 40 years of experience in investment management and finance, including her most recent position as a Managing Director at Nuveen, a TIAA company, where she was responsible for Nuveen's TIAA-CREF Large-Cap Growth Fund with $6.6B in assets.

08:47 EDT Better Choice closes expanded Sereis F financing, accelerates Asian expansion - Better Choice Company announced the closing of an additional $1.1M of Series F financing, bringing the total amount raised to $18.9M. As part of this financing, Management and Board members funded in excess of $11.3M. "In addition to further strengthening our balance sheet, this additional capital allows us to quickly accelerate growth in Asia, specifically China," said Michael Young, Chairman of the Board. BTTR plans to allocate a portion of recent proceeds from our Series F financing to improve our online and physical sales presence in Asia, including an expansion of our internal team, building of inventory and targeted marketing spend. Our 2Q20 gross revenue in Asia was ~$2.4M, which represents a ~16% increase over 1Q20. With this type of exponential growth, we see a tremendous first-mover advantage in Asia and are excited about making this a very meaningful contributor to revenue in the near-term. Our international operations, sold through domestic distribution networks, account for approximately 20% of net sales through the first half of 2020. We could see this reach 40% or more as the market continues to mature."

08:45 EDT Genasys announces FY U.S. law enforcement sales of $1.3M - Genasys announced record fiscal year U.S. law enforcement sales of $1.3M, up 30% over fiscal year 2019. This is the Company's second consecutive fiscal year of record domestic law enforcement sales. "More and more agencies are realizing LRAD's versatility for multiple public safety applications," said CEO Richard Danforth. "By clearly communicating alerts, warnings and instructions, LRAD is helping resolve uncertain situations and enhancing safety for both the public and law enforcement."

08:43 EDT Delta Air Lines sees $150M-$250M in Q4 cash payments from separation programs - The company offered voluntary separation and early retirement programs to employees during the September quarter. Approximately 18,000 employees participated in the programs, with most leaving the company August 1, resulting in a $3.1B restructuring charge in the September quarter, which is reflected in "Restructuring charges" on the Consolidated Statement of Operations. Cash payments in connection with these programs totaled $813M in the September quarter, and these payments are excluded from daily cash burn figures. The company anticipates an additional $150M-$250M in cash payments in the December quarter, $600M in 2021 and the remaining payments in 2022 and beyond.

08:41 EDT Trxade Group's Bonum Health, SingleCare enter prescription savings partnership - Trxade Group announced that its Bonum Health subsidiary has partnered with SingleCare to enhance Bonum's enterprise telehealth solutions with prescription discounts powered by SingleCare. The enterprise service will be offered to national, regional and local pharmacies to promote the benefit to uninsured patients and underserved communities. The increasing cost of healthcare has been exacerbated by the economic pressures of COVID-19, especially for the millions of recently unemployed across America. Bonum Health enables convenient access to affordable care with its clinical technology platform and telehealth solutions that offer virtual medical and provider services at deeply discounted rates. Through these telehealth solutions, an entire household can receive a virtual consultation by board-certified medical doctors, anywhere, at any time. SingleCare is a free prescription savings service that is providing millions of consumers across America with consistently low prices to improve access and adherence to medication. SingleCare is able to save customers up to 80% on their prescriptions.

08:40 EDT Proofpoint announces Content Capture for Microsoft Teams - -Proofpoint (PFPT) announced Content Capture for Microsoft (MSFT) Teams, the latest compliance solution designed for global regulated organizations. With many or most employees suddenly working from home, regulated organizations - more than ever - need to find an effective way for employees to communicate while ensuring digital communications compliance. Firms must capture, retain, and review employee communications to adhere to rules set forth by regulators. It is also critical for firms to be at-the-ready when it comes to search and review of legal matters, particularly in early case assessments or investigations. This is why Proofpoint is committed to innovating in close partnership with productivity and collaboration vendors. Proofpoint provides the following benefits for Teams capture: Capture messages and content in native format, including text, images, and more; Preserve the original context of messages and content at point of capture and in transport; Record edits and deletions of captured content; Ensure what you've captured is stored with complete accuracy.

08:38 EDT WeedMD announces Cannabis 2.0 supply partnership with Pax Labs - WeedMD announced it has entered into a supply agreement with Pax Labs. WeedMD will become a brand partner and supplier for the PAX ERA Collection in Canada, which includes the closed-loop PAX ERA and ERA PRO devices. WeedMD's partnership with PAX will accelerate the growth of the Company's Cannabis 2.0 product strategy as it expands into new formats using its low-cost, quality-produced, strain-specific biomass. As the latest cultivator to launch PAX Era Pods in Canada, WeedMD will produce cannabis oil pods for the 'pen-and-pod' vaporizer devices at the Company's state-of-the-art extraction hub in Aylmer, Ontario. WeedMD will sell Color Cannabis, and Starseed Medicinal-branded oil pods nationwide through supply arrangements with retailers, and its online medical store.

08:37 EDT Victoria Gold reports Q3 2020 gold production of 35,321 ounces - Victoria Gold announces third quarter 2020 gold production of 35,312 ounces and gold revenue of C$80M at an average realized price of US$1,886 per ounce of gold. Mr. John McConnell, President and CEO commented, "This has been another strong quarter for operations at Eagle particularly given the increased challenges of ramping up a new mine during the unprecedented conditions related to COVID-19. There were no Lost Time Incidents during the quarter and we have achieved a very impressive 2.7 million hours LTI free. Effective health protection measures put in place have safeguarded employees and local residents and enabled mine operations to continue, with no suspected or confirmed cases of COVID-19 at site. Our first quarter of Commercial Production included record tonnes mined including ore and waste, tonnes stacked on the heap leach pad and gold production and sales. We are in the late stages of operational ramp-up and the team has done a commendable job in identifying and rectifying the few remaining bottlenecks. This will place us in a good position to continue to increase production in Q4 2020 and into 2021."

08:36 EDT Wipro board approves share buyback of up to $1.3B

08:35 EDT Realty Income appoints Christie Kelly as CFO - Realty Income (O) announced that Christie Kelly will become Executive Vice President, CFO and Treasurer. Kelly joined the company's Board of Directors in November 2019 and currently serves as a member of the Audit Committee. The appointment of Kelly to CFO will take effect January 19, 2021, at which time Ms. Kelly will resign from the company's Board of Directors. Kelly is the former Global CFO of Jones Lang LaSalle (JLL). She worked with JLL from 2013 - 2018, bringing with her 25 years of experience in financial management, international real estate, mergers and acquisitions, information technology and investment banking.

08:34 EDT Cerus awarded five-year contract with FDA with a value of $11.1M - Cerus announced it was awarded a five-year contract with the U.S. Food and Drug Administration, FDA, for the development of next-generation compounds to optimize pathogen reduction, PR, treatment of whole blood to reduce the risk of transfusion-transmitted infections. The contract value totals $11.1M. This research is consistent with the FDA's strategy for developing proactive, foundational interventions to ensure blood safety and availability. Given the possible benefits of whole blood transfusion2, pathogen reduced whole blood has the potential to fundamentally reshape the support of patients with massive hemorrhage.

08:32 EDT ClearSign Combustion receives order for three burners - ClearSign Technologies announces it has received an order for three burners to be installed in an existing process heater at a California storage and transportation terminal. The burners were sold and will be installed by ClearSign's channel affiliate, California Boiler, who will be a subcontractor to the overall project management company, R. A. Nichols Engineering.

08:31 EDT Twin River Worldwide acquires Bally's brand - Twin River Worldwide Holdings announced that it has purchased the iconic Bally's brand previously owned by Caesars Entertainment. This acquisition will allow Twin River to maintain the Bally's name for the Atlantic City property that it has agreed to purchase from Caesars Entertainment pursuant to the previously announced purchase agreement and enables the Company to rebrand virtually all of its portfolio properties under the Bally's name and logo. As part of the deal, Twin River has agreed to provide Caesars Entertainment a perpetual license to use the Bally's brand at its existing Bally's Las Vegas Hotel & Casino property. Financial terms were not disclosed.

08:28 EDT Afya Limited announces acquisition of iClinic for R182.7M - Afya Limited announced the acquisition of 100% of the total share capital of iClinic, through its wholly-owned subsidiary Afya Participacoes S.A. iClinic is a SaaS model physician focused technology company and the leading practice management software in Brazil. They empower doctors to be more independent and have more control over their careers by digitalizing their daily routine, so they can increase their productivity and deliver better healthcare. Their portfolio includes: lectronic Medical Record: First electronic medical record as a SaaS model in Brazil focused on the physician experience. Clinical Management System: with this software doctors can schedule patients online, organize their financial records, use market tools to promote their clinics and others. Telemedicine: platform to provide online consultations fully integrated with doctor's schedule and records. Physicians Marketplace: website that connects doctors and patients to schedule consultations. The net purchase price was R$182.7 million, of which: 61.5% was paid in cash, and 38.5% was paid in Afya's stock.

08:24 EDT Barrick Gold signs definitive agreement with Bullfrog Gold - Barrick Gold announced that wholly-owned subsidiaries of Barrick and Bullfrog Gold have entered into a definitive purchase agreement pursuant to which Barrick will sell to BFGC all of Barrick's mining claims, historical resources, permits, rights of way and water rights in the Bullfrog mine area. The transaction is expected to close during the fourth quarter of 2020. The Mineral Lease and Option to Purchase Agreement between a subsidiary of BFGC and Barrick dated March 23, 2015, as amended, has been terminated, eliminating Barrick's back-in right. As previously announced by BFGC, in consideration, Barrick will receive 54,600,000 units. Each Unit is comprised of one share of common stock of BFGC and one whole warrant that entitles the holder to purchase one share of capital stock in BFGC at an exercise price of $0.30 for four years from the date of closing. On closing, Barrick will own approximately 16.8% of BFGC's total issued and outstanding Shares or approximately 19.9% of BFGC's Shares on a fully diluted basis. BFGC will also grant to Barrick a 2% NSR royalty on all minerals produced from the claims, decreasing to a minimum 0.5% NSR royalty on certain claims already subject to royalties. Concurrently, Augusta Investments, and certain other persons identified by Augusta, entered into subscription agreements with BFGC pursuant to which BFGC will issue and sell to the purchasers an aggregate of 110,000,000 Units for total consideration of $22,000,000. The closing of the transactions are inter-conditional and subject to other customary conditions. Barrick is acquiring the Units in BFGC for investment purposes. Depending on market conditions and other factors, including BFGC's business and financial condition, Barrick may acquire additional Units or other securities of BFGC or dispose of some or all of the Units or other securities of BFCG that it owns at such time. In connection with the transaction, Barrick, Augusta and BFGC will enter into an investor rights agreement on closing pursuant to which, among other rights, so long as Barrick maintains a minimum of 10% ownership in BFGC, Barrick will be granted the right to appoint one director to BFGC's Board of Directors and the right to participate in future BFGC equity issuances to maintain its then-current pro rata interest in BFGC.

08:22 EDT Digirad's KBS signs Phase 3 of contract for U.S. Army housing units - Digirad Corporation announced that KBS Builders has signed Phase 3 of its previously announced project with Tocci Building Corporation. Phase 3 of this project, valued at $1.5M, increases the total project size by an additional 26 building modules and 6 living units. All three phases of this project have a combined value of $6.7M and are for the manufacture of 124 building modules to be used in the production of 28 single-family and townhouse units for the U.S. Army Natick Soldier Systems Center in Natick, MA. Phase 1 of the project has been completed. The townhouse and duplex style homes under Phase 2 of this project have commenced and building set and erection is scheduled to start later this month. All 124 modular units are being manufactured at KBS's plant in South Paris, ME, which has a production capacity of 500 to 600 building modules per year.

08:21 EDT Osisko Gold signs agreement with Lhtako Dene Nation for Cariboo Gold Project - Osisko Gold Royalties announced that the Lhtako Dene Nation and Barkerville Gold Mines, its wholly owned subsidiary and future 100% subsidiary of Osisko Development Corp., have entered into a life-of-project agreement to facilitate the development of the Cariboo Gold Project. The Project Agreement achieves our common goal to provide Project-related opportunities and benefits for current and future generations of the LDN people and reflects our ongoing commitment to continually strengthen and expand our relationship. The Project Agreement has been realized through the culmination of committed and conscientious efforts of LDN, BGM and our respective negotiating teams. It builds upon initial Engagement Protocol and subsequent Relationship Agreement. Specific terms of the Project Agreement remain confidential, however, it puts in place a framework for BGM and LDN to work together during all stages of the Project, including the terms under which the Project will be developed with the consent and support of the LDN.

08:20 EDT Novavax appoints leadership team to advance NanoFlu through licensure - Novavax announced the formation of a leadership team to advance NanoFlu to regulatory licensure and the promotion of Russell Wilson, J.D./M.B.A., to EVP and the newly-created role of NanoFlu General Manager. Mr. Wilson will focus exclusively on leading efforts to advance NanoFlu, the company's influenza vaccine candidate, through global licensure, as well as the exploration of a combined influenza/COVID-19 vaccine that could be used in a post-pandemic setting. Novavax announced results of its successful NanoFlu pivotal Phase 3 clinical trial earlier this year and intends to seek regulatory approval from the U.S. Food and Drug Administration under the accelerated approval pathway previously granted to the company. Wilson joined Novavax in 2011 and was most recently responsible for global business development, quality and program management functions across the company's entire pipeline. In his new role, he will lead a team that will work closely with the broader Novavax team to obtain licensure for NanoFlu from FDA and other global authorities, as well as evaluate the development of a pentavalent NanoFlu/NVX-CoV2373 vaccine. The new NanoFlu leadership team includes several Novavax veterans who led the successful development of the vaccine through completion of its successful pivotal Phase 3 clinical trial. This team has also recently completed key activities related to the development of NVX-CoV2373. In addition to Mr. Wilson, the team will be comprised of the following leaders: Tim Hahn, Ph.D., Senior Vice President of CMC for NanoFlu, has led all CMC activities for NanoFlu since the beginning of the program. Most recently, Dr. Hahn led the establishment of a global supply chain for Novavax' Matrix-M adjuvant. Matrix-M is a key component of both the NanoFlu and NVX-CoV2373 vaccines. Vivek Shinde, M.D., Vice President of Clinical Development for NanoFlu, has served as the clinical lead for the NanoFlu program since its inception and through Phase 3. Dr. Shinde also recently led the initiation of the Phase 2b clinical trial in South Africa for NVX-CoV2373.

08:16 EDT Silicom selected by Tier 1 Mobile Operator - Silicom announced that a Tier 1 Mobile Operator has selected Silicom's architecture for next-generation Distribution Units, which supports both 4G and 5G deployments, for use in field trials planned to take place during the next several months. The architecture selected is based on Silicom's Edge Units designed originally for use in SD-WAN/NFV applications. Since the original design was modular, Silicom was able to customize the solution quickly for use in the mobile network DU and to rapidly integrate Silicom's 4G/5G Smart Cards into it.

08:14 EDT NeuBase Therapeutics adds Peter Nielsen to Scientific Advisory Board - NeuBase Therapeutics announced the addition of Peter Nielsen, Ph.D. to its scientific advisory board. Dr. Peter Nielsen is a leading expert in gene targeting, RNA interference and chemical replication and translation and was one of the inventors of PNAs in 1991. He is currently a professor at the University of Copenhagen where his lab focuses on PNAs in regard to drug discovery, gene targeting, antisense principles, cellular and in vivo delivery and administration of biopharmaceuticals.

08:13 EDT Advent Technologies to become publicly listed through AMCI Acquisition merger - Advent Technologies and AMCI Acquisition Corp announced that they have entered into a definitive agreement and plan of merger for a business combination that would result in Advent becoming part of a publicly listed company as a wholly-owned subsidiary of AMCI. Upon the closing of the transaction, the combined company will operate as Advent Technologies and its common stock will be listed on the Nasdaq. The combined company will continue to operate under the current Advent management team, led by CEO Vasilis Gregoriou. The company said capital from this transaction, combined with AMCI's expertise, will advance the development and manufacturing of Advent's next-generation fuel cell technology for the markets of transportation, aviation, and off-grid power generation. The business combination values Advent at a $358M pro forma post-money enterprise value at a share price of $10.00, assuming no redemptions by AMCI shareholders and no purchase price adjustments. The boards of directors of both Advent and AMCI have unanimously approved the proposed transaction, which is expected to be completed in Q4 or early 2021, subject to, among other things, the approval by AMCI's shareholders and Advent's shareholders, satisfaction of the conditions stated in the merger agreement and other customary closing conditions. In connection with the business combination, AMCI will also amend its warrants at the closing of the business combination to cash-out all of its outstanding warrants for a payment of $1.50 per warrant, subject to approval by its warrantholders.

08:12 EDT Esports Entertainment signs agreement with LA Kings, LA Galaxy - Esports Entertainment Group announced that it has entered into an agreement with AEG to become the official esports tournament provider for the LA Kings of the National Hockey League and LA Galaxy of Major League Soccer. This is a new category for the LA Kings and LA Galaxy and the Company's first partnership with an MLS and NHL team. Under the terms of the agreement, brokered by AEG Global Partnerships, the Company will exclusively host branded tournaments for the LA Kings and LA Galaxy on its Esports Gaming League platform, providing new ways for the teams to engage their fans while demonstrating the crossover appeal of esports to traditional sports fans and organizations.

08:10 EDT Citi reports Q3 efficiency ratio 63.4%, ROE 6.7%, RoTCE 7.9% - Reports Q3 SLR 6.7% and payout ratio 101%. The company said, "Our capital position strengthened during the quarter with our Common Equity Tier 1 ratio increasing to 11.8% and our Tangible Book Value per share increasing to $71.95. We remain committed to returning capital to our shareholders, subject to the industry-wide approach determined by the Federal Reserve."

08:10 EDT CytRx highlights use of drug aldoxorubicin in pancreatic cancer study - CytRx highlighted that ImmunityBio, and NantKwest, have announced the addition of a third cohort to their ongoing Phase 2 study of a novel combination immunotherapy - which includes CytRx's licensed drug aldoxorubicin - for locally advanced or metastatic pancreatic cancer, QUILT-88. According to the companies, the third cohort will enable pancreatic cancer patients who have failed all approved standards of care to participate in the study. As previously noted in CytRx's October 7 press release regarding the reportedly promising treatment delivered to former Senator Harry Reid for his stage IV pancreatic cancer, this randomized, open-label study is evaluating the safety and efficacy of a combination immunotherapy that includes aldoxorubicin, ImmunityBio's IL-15 superagonist Anktiva NantKwest's PD-L1 t-haNK, and standard of care. The study results will be compared to standard of care chemotherapy for first- and second-line treatment. However, the third-line cohort is a single arm with no comparator. Each cohort will be evaluated independently to provide more precise comparative data for each disease stage. "Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States and requires significant advancements in treatment to improve outcomes for patients," said Steven A. Kriegsman, CytRx's Chairman and Chief Executive Officer. "We commend the Companies for adding a third cohort and expanding this Phase 2 study of their combination immunotherapy that includes aldoxorubicin. We are encouraged that aldoxorubicin continues to play a role in their mission to recruit and amplify the power of the human body's own immune system to target and destroy even the most difficult cancer cells." CytRx out-licensed global development, manufacturing and commercialization rights for aldoxorubicin to ImmunityBio in 2017. The Company has an agreement with ImmunityBio that can yield up to $343M in potential milestone payments as well as prospective royalties on sales of aldoxorubicin.

08:07 EDT electroCore provides business update - The company said, "COVID-19: The launch of gammaCore Sapphire CV for treatment of known or suspected COVID patients under the previously announced Emergency Use Authorization is proceeding. gammaCore Sapphire CV is available by prescription through our VA/DoD channels, from Premier Specialty Pharmacy, and access to telehealth consults from health care providers are being offered through the UpScript telehealth portal at www.getgammacore.com. We are pleased with the level of interest this initial launch has generated for both gammaCore Sapphire CV as well as our headache products. As our understanding of the disease has evolved and in-patient treatment regimens have changed, the enrollment criteria for SAVIOR 1 and SAVIOR 2 trials in hospitalized COVID patients have proven to be more challenging than originally anticipated. We continue to monitor COVID-19 levels near the two sites conducting the study and are discussing possible modifications to the protocol with the Investigators. Federal Supply Schedule: During the third quarter of 2020, 68 Department of Veterans Affairs (VA) and Department of Defense military treatment facilities purchased gammaCore products as compared to 67 during the second quarter of 2020, 64 during the first quarter of 2020, 54 during the fourth quarter of 2019 and 48 during the third quarter of 2019. Also, during the third quarter of 2020, the company shipped approximately 1,600 paid months of therapy pursuant to VA and DoD originating prescriptions, compared to 988 paid months of therapy in the second quarter of 2020, 1,084 paid months of therapy during the first quarter of 2020, 829 during the fourth quarter of 2019 and 553 during the third quarter of 2019. In light of the ongoing COVID-19 pandemic, the company's ability to visit VA doctors and facilities remains limited. However, the VA quickly and effectively adopted telehealth capabilities, with the number of daily sessions increasing more than 10x since the start of the pandemic, according to a news release from the Office of Public and Intergovernmental Affairs. The company continues to navigate through this challenging business environment and remains well positioned to resume all available outreach activities if and when the pandemic subsides. Outside of the U.S.: During the third quarter of 2020, electroCore shipped approximately 1,020 paid months of therapy outside of the United States, as compared to 938 paid months of therapy during the second quarter of 2020 and 1,008 during the first quarter of 2020. Since April 2019, gammaCore has been reimbursed by NHS England's Innovation and Technology Payment Program for the treatment of cluster headache in adults. The ITP Program is designed to support the adoption of innovations and technologies in the NHS market through the removal of significant financial barriers for both commissioners and providers. Earlier this month, the ITP Program for gammaCore was again extended for a six-month period through March 1, 2021 with the option for three additional years. The total contract value, assuming exercise of the three-year option, could be up to approximately $4.6 million at recent exchange rates. Perhaps more importantly, the company views this extension as another meaningful validation of nVNS technology. More than 55,000 adults in the U.K. suffer from cluster headache, a truly debilitating condition with few effective treatment options. Commercial: During the first half of 2020, the company restructured and streamlined its commercial distribution channel. All of the inventory placed in the commercial channel during 2019 was fully dispensed by June 30, 2020. As a result, the company was able to recognize a full quarter of replenishment orders during the period ended Sep 30, 2020. The company is monitoring pharmacy inventory on an ongoing basis and expects ongoing contribution from commercial replenishment orders in the coming quarters. mTBI/PTSD VA Study. In the quarter ended September 30, 2020, the company was notified that the VA has agreed to sponsor a quadruple blind, randomized, sham-controlled clinical trial of nVNS as a potential treatment for mild traumatic brain injury and Post-Traumatic Stress Disorder. The trial is being sponsored by the VA's Office of Research and Development at the Atlanta VA Medical Center. mTBI and PTSD are of significant concern for the VA in light of recent conflicts in Iraq and Afghanistan, and it is estimated that up to 56% of mTBI patients have co-morbid PTSD, making the combined conditions more common than each individually. This is an important study for the company with the potential to introduce gammaCore in an entirely new indication and further leverage the company's existing relationship with the VA. Clinical: In addition to COVID-19, gammaCore investigator initiated trials continue to progress in stroke, subarachnoid hemorrhage, certain rheumatologic conditions, and as outlined above, in mTBI/PTSD which is supported by the VA."

08:05 EDT Gamida Cell and Be The Match BioTherapies expand strategic collaboration - Gamida Cell and Be The Match BioTherapies announced an expansion of their existing strategic collaboration for omidubicel, Gamida Cell's advanced cell therapy in Phase 3 clinical development as a potentially life-saving treatment option for patients in need of an allogeneic hematopoietic stem cell (bone marrow) transplant. The broadened agreement represents an important step in both organizations' patient access efforts and in Gamida Cell's preparation for potential approval by the U.S. Food and Drug Administration, FDA. The original partnership agreement between the organizations focused on the omidubicel development program and leveraged a wide range of Be The Match BioTherapies' capabilities and services. This included providing cellular source material from the Be The Match Registry, which offers the most ethnically diverse listing of potential donors and umbilical cord blood units in the world, with 22 million potential donors and more than 300,000 umbilical cord blood units, as well as cell therapy supply chain and logistics management services. In building upon the existing collaboration, Gamida Cell will work through Be The Match BioTherapies for the ordering and supply of cord blood units, which serve as the starting material for omidubicel. The expanded agreement is designed to provide a smooth process throughout the omidubicel therapy supply chain.

08:03 EDT Kingsway Financial to acquire PWI Holdings for $24.5M - Kingsway Financial (KFS) announced the signing of a definitive agreement to acquire PWI Holdings from ADESA Dealer Services, a subsidiary of KAR Auction Services (KAR), d/b/a KAR Global, subject to certain regulatory approvals and other customary closing conditions. PWI, through its subsidiaries Preferred Warranties, Inc., Superior Warranties, Inc., Preferred Warranties of Florida, Inc., and Preferred Nationwide Reinsurance Company, Ltd, markets, sells and administers vehicle service contracts in all fifty states, primarily through a network of automobile dealer partners. The purchase price for the acquisition is $24.5M and is expected to close prior to year-end, pending receipt of the requisite regulatory approvals and satisfaction of other customary closing conditions. Kingsway expects to fund the purchase price via a mix of cash on hand and third-party financing. Ice Miller LLP served as legal counsel to Kingsway and Taft Stettinius & Hollister LLP served as legal counsel to KAR in connection with the transaction.

08:02 EDT Celldex initiates Phase 1b study of CDX-0159 - Celldex Therapeutics announced that enrollment has opened and the first patient has been dosed in its randomized, double-blind Phase 1b study of CDX-0159 in patients with chronic spontaneous urticaria. CDX-0159 is a humanized monoclonal antibody developed by Celldex that binds the KIT receptor with high specificity and potently inhibits its activity. The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. As previously presented, CDX-0159 demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, indicative of systemic mast cell ablation in a Phase 1a single dose, healthy volunteer study. The Phase 1b study is a randomized, double-blind, placebo-controlled clinical trial designed to assess the safety of multiple ascending doses of CDX-0159 in patients with CSU who remain symptomatic despite treatment with antihistamines. Secondary and exploratory objectives include pharmacokinetic and pharmacodynamic assessments, including measurement of tryptase and stem cell factor levels and clinical activity outcomes as well as quality of life assessments. The study is expected to enroll approximately 40 patients with CSU across four cohorts. CDX-0159 dosing for each cohort is as follows: Cohort 1 - 0.5 mg/kg Q 4 weeks; Cohort 2 - 1.5 mg/kg Q 4 weeks; Cohort 3 - 3 mg/kg Q 8 weeks; and,Cohort 4 - 4.5 mg/kg Q 8 weeks. CDX-0159 will be administered intravenously as add on treatment to H1-antihistamines, either alone or in combination with H2-antihistamines and/or leukotriene receptor agonists.

07:52 EDT Sabina Gold & Silver announces assay results from Umwelt High-Grade Corridor - Sabina Gold & Silver Corp announced further high grade assay results from drilling of the upper portions of the high-grade corridor at the Umwelt Underground resource on its 100%-owned Back River Gold Project in Nunavut, Canada. Internal studies conducted earlier this year suggest that mining higher-grade underground material at the beginning of the mine life could have a significant positive impact on project economics by increasing gold production in the early years. Drilling was designed to delineate and detail the nature of the high-grade structure at Umwelt, which has never been discretely targeted. During the 2020 field program, nine holes were drilled, proving the hypothesis that additional high-grade corridors exist between the Vault Zone at depth and the bottom of the proposed open pit at Umwelt. This year's drilling focused on a zone directly under the proposed Umwelt open pit at a depth that ranges from 135m to 285m below surface, over a plunge extent of approximately 300 m. All seven drill holes targeting this zone returned exceptional widths of gold mineralization, up to 2-3 times the average grade of the Umwelt underground reserve. The V2 Zone is very similar to the Vault Zone, further supporting the concept of additional high-grade underground corridors within the Umwelt deposit. These results will be incorporated into an updated Feasibility Study expected to be released in the 1st Quarter of 2021. To further explore the high-grade corridor at Umwelt, the Company is moving forward with an underground exploration ramp that can facilitate further exploration drilling as well as provide for bulk sampling. The exploration ramp could provide early access to continue exploring the V2 Zone with approximately 1500m of ramp development. The initial surface work and mobilization of equipment required to support the exploration ramp is underway, with collaring of the decline expected in early 2021. These assay results are the final three holes from the V2 Zone and include: hole 20GSE581 which returned 16.59 g/t over 20.55 m hole 20GSE582 which returned 14.78 g/t over 22.75 m and hole 20GSE584 which returned 14.78 g/t over 24.80 m. One additional drill hole 20GSE576 targeted mineralization located 200 m below the V2 zone with results as described in table 3.0. Highlights from previous drilling at V2 as reported includes 15.15 g/t over 19.40 m in hole 20GSE571 and 19.89 g/t over 32.20 m in drill hole 20GSE575C. Sabina's focus on structural studies over the last three years has yielded strong exploration opportunities across the Goose Property and driven positive resource optimization and growth at Umwelt. As part of this focused approach, drilling in 2020 was committed to better define the continuity of higher-than-average-grade potential within the Umwelt underground over approximately 815 m of plunge length that extends north from the Vault zone towards the boundaries of the Umwelt Open Pit. Mineralization intersected by drill holes 20GSE581, 20GSE582 and 20GSE584 continues to demonstrate the exceptional tenor of mineralization associated with the Umwelt gold structures and is an excellent example of many of the best features characterizing Back River gold zones. Iron formation consists of moderate to strong chlorite, actinolite and silica alteration with pervasive quartz veining hosting common sulphides including pyrrhotite and arsenopyrite occurring heavily throughout the zone. These three drill holes are excellent examples of the robust mineralization style that includes heavy sulphidation of the host rock with exceptional grade occurring proximal to the lower contact of the iron formation units. Rheologic contrast of the stratigraphy and high-iron content of the host horizon are interpreted as favourable features in establishing high quality deposits at Back River. Visible gold was observed in all holes targeting the Umwelt underground V2 Zone reported to date. Drilling has now completed with two phases at Umwelt through nine holes supporting the objective. Upon receipt of the final Versatile Time Domain Electromagnetic data collected at the Goose property and other regional areas as part of this year's field program, Sabina will undertake additional forward modelling and rigorous data review in preparation for additional exploration drilling in 2021. With the help of experts, this new dataset will be studied at known deposits to properly characterize physical properties of mineralization and key structures. This characterization will then play an important role in target prioritization and evaluation of regional areas. Exploration drilling has also been completed at several high-priority targets however results are pending at this time

07:47 EDT Apollo Infrastructure Funds, Altius Renewable Royalties announce joint venture - Apollo Global Management (APO) announced that certain funds managed by its affiliates have formed a joint venture with Altius Minerals Corporation (ATUSF) subsidiary Altius Renewable Royalties to accelerate the growth of Great Bay Renewables, the US-based operating subsidiary of Altius and a leading provider of renewable energy development capital in North America. Apollo Funds expect to invest up to $200M and will have the opportunity to acquire up to a 50% stake in Great Bay, the proceeds of which will be used by Great Bay to invest in prominent renewable energy development platforms in North America. Through the investment, Apollo's infrastructure strategy becomes the first in its asset class to fund renewable royalties and expects to establish a leadership position in the space. Formed in 2017, Great Bay provides strategic capital to renewable energy developers via a flexible, proprietary royalty structure that can be applied to all stages of a renewable project's life cycle and help accelerate the development process in a non-dilutive structure. The company is led by President and CEO Frank Getman and a management team with extensive experience in renewable energy development, financing, and operations, across a range of renewable technologies and asset types. Apollo joins the teams at Great Bay and Altius in seeing significant opportunities to invest in wind, solar and energy storage projects in the US and Canada over the next decade. Since inception, Great Bay has invested more than $60M in leading developers such as Apex Clean Energy and Tri Global Energy, which together are advancing over 18 gigawatts of wind and solar projects.

07:36 EDT LabCorp, The Commons Project enter partnership to allow access to test results - LabCorp and The Commons Project announced a strategic partnership to allow people to securely access their LabCorp test results via CommonHealth, the privacy-preserving Android app that enables users to collect, store and use their personal health information. LabCorp is the first major commercial lab to integrate with CommonHealth, which is also working with a wide range of other health care providers.

07:34 EDT Stryker extends cash tender offer for shares of Wright Medical - Stryker (SYK) announced that Stryker B.V., an indirect, wholly owned subsidiary of Stryker, has extended the offering period of its previously announced cash tender offer for all outstanding ordinary shares of Wright Medical Group N.V. (WMGI). The tender offer is being made pursuant to the purchase agreement, dated November 4, 2019, among Stryker, Stryker B.V. and Wright Medical. The tender offer is now scheduled to expire at 5:00 p.m., Eastern Time, on October 28, 2020, unless the tender offer is further extended or earlier terminated in accordance with the purchase agreement.

07:34 EDT Nephros announces release of DialyPath endotoxin assay - Nephros announced availability of DialyPath, an assay that estimates endotoxin levels in dialysis water samples. Water sampling is generally required in dialysis clinics to ensure that no waterborne contamination is present. Of particular interest are endotoxins, which are gram-negative bacterial fragments that can cause inflammation and other complications in dialysis patients. DialyPath is an on-site test that measures endotoxin levels in about two hours. DialyPath results correlate highly with data from the limulus amebocyte lysate assay, currently the industry standard for endotoxin measurement. DialyPath uses qPCR technology to quantify DNA target segments in a water sample, which are matched to a DNA segment that is found in all gram-negative bacteria. From these results, DialyPath uses proprietary algorithms to estimate the number of endotoxin units in a dialysis water sample.

07:32 EDT JPMorgan still sees FY20 net interest income about $55.5B, market dependent - Sees FY20 adjusted expense of about $66B. Comments taken from Q3 earnings conference call presentation slides.

07:27 EDT Royal Caribbean may seek to further reduce average monthly expenses - Royal Caribbean may seek to further reduce its average monthly expenses under a further prolonged non-revenue scenario. This includes consideration of additional vessels heading to cold layup as well as further assessment of our US shoreside workforce, including those coming back from furlough.

07:26 EDT Royal Caribbean had about $1.8B in customer deposits as of June 30 - The company believes that the customer deposits balance is not materially different as of September 30, 2020 as compared to the June 30, 2020 balance. Approximately 50% of the guests booked on cancelled sailings have requested cash refunds.

07:25 EDT Royal Caribbean: Pandemic continues to have material impact on results - In a regulatory filing, Royal Carribean said: "The disruptions to our operations resulting from the COVID-19 pandemic have had, and continue to have, a material negative impact on our financial condition and results of operations. The outbreak of COVID-19 has resulted in an unprecedented global response to contain the spread of the disease. These global efforts have resulted in travel restrictions and created significant uncertainty regarding worldwide port closures and availability. As part of the global containment effort, we previously announced a voluntary suspension of our four global cruise brands' operations: Royal Caribbean International, Celebrity Cruises, Azamara and Silversea Cruises effective March 13, 2020, which has been extended through at least November 30, 2020, excluding sailings from Hong Kong. In addition, although Royal Caribbean International has received approval from the Singapore Government to pilot cruises starting in December 2020, Royal Caribbean International will be suspending all sailings departing from Australia and New Zealand on or before December 31, 2020. Celebrity Cruises will also be suspending their full 2020/21 Winter program in Australia and Asia. Additionally, Azamara will be suspending their 2020/21 Winter sailings throughout Australia and New Zealand, South Africa and South America. In connection with these suspensions, we have repatriated over 44,000 crew members to their home countries around the globe. Containment efforts as a result of the disease and continued disruptions to travel and port operations in various regions may result in further suspensions."

07:19 EDT Vista Outdoor sees Remington acquisition accretive to earnings in FY22 - Vista Outdoor announced the successful closing of the acquisition of certain assets related to Remington Outdoor Company's ammunition and accessories businesses, and related intellectual property for a gross purchase price of $81.4M. Vista Outdoor expects the transaction to be accretive to earnings, excluding transaction and transition costs, in Fiscal Year 2022. For calendar year 2019, aggregate net sales by the Remington ammunition and accessories brands were approximately $200M.

07:16 EDT Finance of America Equity Capital to go public through Replay Acquisition merger - Finance of America Equity Capital and Replay Acquisition Corp., a publicly traded special purpose acquisition company, agreed to a business combination that will result in Finance of America becoming a publicly listed company. Finance of America connects borrowers with investors. The company operates in four large markets including Mortgage, Reverse Mortgage, Commercial Real Estate, and Fixed Income Investing. Brian Libman, founder and chairman of Finance of America, Patricia Cook, CEO, and Graham Fleming, president, will continue to lead the company. Implied equity value of the combined company at closing is approximately $1.9B. The transaction implies an equity valuation at closing for the combined company of $1.9B. Top-tier institutional investors have committed to invest $250M in the form of a PIPE at a price of $10.00 per share of the combined company's Class A common stock immediately prior to the closing of the transaction. Estimated cash proceeds will consist of the PIPE in addition to Replay Acquisition's $288M of cash in trust, subject to redemptions. It is anticipated that the combined company will begin with a minimum of $250M of cash and cash equivalents. Pro forma for the transaction, assuming no redemptions by Replay Acquisition's public shareholders, Management, entities managed by Finance of America's founder and funds managed by Blackstone Tactical Opportunities will own approximately 70% of the combined company. Over half of the sponsor's founder shares of Replay Acquisition will be deferred and subject to share price hurdles. The board of Replay Acquisition and the board of Finance of America's parent company have unanimously approved the transaction. The transaction will require the approval of the shareholders of Replay Acquisition, and is subject to other customary closing conditions, including the receipt of certain regulatory approvals. The transaction is expected to close in the first half of 2021.

07:13 EDT Gossamer Bio won't continue further development of GB001 in rhinosinusitis

07:12 EDT Gossamer Bio announces results for Phase 2 trials of oral GB001 - Gossamer Bio announced topline results from its Phase 2b LEDA trial in patients with moderate-to-severe eosinophilic asthma and its Phase 2 TITAN trial in patients with chronic rhinosinusitis. The LEDA trial enrolled 480 patients with uncontrolled, moderate-to-severe eosinophilic asthma and assessed the effect of oral GB001 add-on therapy to standard of care over 24 weeks, comparing three dose groups of once-daily, oral GB001 to placebo. The primary endpoint of the trial was not met, though consistent and meaningful numeric reductions in the odds of asthma worsening as compared to placebo were observed across all GB001 groups, Gossamer said. Consistent reductions for each GB001 group as compared to placebo were seen across all individual components of the asthma worsening endpoint. The proof-of-concept TITAN trial enrolled 97 patients with chronic rhinosinusitis with and without nasal polyps and assessed treatment with GB001 40 mg vs. placebo over 16 weeks. Neither the primary nor the secondary endpoints of the trial were met. The safety and tolerability of GB001 40 mg was generally consistent with that observed in the LEDA Study. Gossamer said: "We do not plan to continue further development of GB001 in chronic rhinosinusitis." "While we did not achieve statistical significance on the primary endpoint in the LEDA Study, we are encouraged by the consistent results observed for all three doses of once-daily, oral GB001 therapy across the primary and secondary endpoints," said Sheila Gujrathi, M.D., Co-Founder and CEO of Gossamer. "We believe these data provide important information for designing a well-powered Phase 3 program for GB001 in severe asthma. We plan to engage in global regulatory discussions in order to inform our thinking around potential partnerships or strategic alternatives for this program."

07:11 EDT First Majestic reports Q3 total production of 5.2M silver equivalent ounces - First Majestic Silver announces that total production in the third quarter of 2020 reached 5.2 million silver equivalent ounces consisting of 3.2 million ounces of silver and 25,771 ounces of gold. Quarterly silver and gold production increased 72% and 63%, respectively, compared to the prior quarter following Mexico's Ministry of Health's Federal Decree requiring all non-essential businesses, including mining, to temporarily suspend activities throughout most of April and May in response to the global pandemic. In the first nine months of 2020, the Company produced 8.1 million ounces of silver and 73,738 ounces of gold for a total production of 14.9 million silver equivalent ounces. La Encantada produced 978,416 silver ounces, representing a 92% increase from the prior quarter and the second highest quarterly production since 2014. La Encantada is now expected to fully recover its lost silver ounces due to the COVID-19 shutdown by year-end. San Dimas produced 1,678,075 ounces of silver and 18,268 ounces of gold, representing the highest quarterly silver production since acquiring the asset in May 2018. Santa Elena produced 502,375 ounces of silver and 7,428 ounces of gold, representing an increase of 126% and 102%, respectively, compared to the prior quarter. Liquid Natural Gas storage tanks were delivered and installed at Santa Elena during the quarter. The project remains on schedule for commissioning in Q1 2021 and is expected to significantly reduce energy costs going forward. Construction of a second portal, including the initial development of a new parallel south ramp, at Santa Elena's Ermitano project was completed during the third quarter.At the end of the third quarter, 26 exploration drill rigs were active across the Company's mines and projects consisting of 14 rigs at San Dimas, eight rigs at Santa Elena, two rigs at La Encantada and two rigs at La Parrilla. Total exploration metres planned for 2020 have been increased by 24,000 metres to a total target of 163,000 metres for the full year. The Company held a balance of $232.4 million in cash and cash equivalents at the end of the quarter.

07:10 EDT Gossamer Bio: TITAN study did not meet primary, secondary endpoints

07:08 EDT Ionis Pharma's inhaled antisense medicine shows potential as treatment for CF - Ionis Pharmaceuticals announced that data from a clinical trial of IONIS-ENAC-2.5Rx demonstrated a significant decrease in the expression of epithelial sodium channel in subjects with cystic fibrosis. The study showed a mean 55.6% decrease in ENaC mRNA expression at the 75 mg dose in the multidose segment of the trial. The study represents the first time an antisense medicine delivered directly to the lung via a nebulizer has shown a significant reduction in ENaC messenger RNA levels. In preclinical studies, ENaC mRNA reductions of 40% or more resulted in significant improvement in mouse models of CF lung disease.

07:08 EDT Twist Bioscience, Neogene announce strategic partnership for T cell therapies - Twist Bioscience and Neogene Therapeutics announced a broad strategic partnership. The companies will leverage Neogene's proprietary expertise in targeting tumor neo-antigens, mutated proteins found in cancer cells due to cancer-associated DNA mutations, together with Twist's DNA synthesis platform and product lines to develop personalized chimeric antigen receptor, or CAR, T cell therapies and T cell receptor, or TCR, therapies for patients with cancer. Under the terms of the collaboration, Neogene and Twist will work together to develop novel tools for T cell therapies. Twist Biopharma, a division of Twist Bioscience, will create a specialized T cell receptor, or TCR, library for Neogene with the goal of discovering engineered TCRs against two specified T cell targets in cancer for future Neogene personalized T cell therapies. Twist Biopharma also will discover antibodies with specific function, affinity and specificity to two oncology targets for future Neogene CAR-T therapies. These antibodies will have single point specificity to their target providing the potential for novel CAR-T therapies against such targets. Twist will receive technology access fees as well as milestones and royalties based on key preclinical, clinical and commercial milestones for any antibodies and T cell receptors resulting from the collaboration. Neogene will have exclusive rights to the synthetic TCR library for targeting viral and neo-antigens in the field of oncology.

07:05 EDT Nabriva Therapeutics announces post-hoc analysis of LEAP 1, LEAP 2 trials - Nabriva Therapeutics announced that in a post-hoc analysis of the Lefamulin Evaluation Against Pneumonia 1 and LEAP 2 trials by age, XENLETA demonstrated consistently high efficacy and similar safety and tolerability profiles across all patient groups, including adults over 65 years of age who are at higher risk of morbidity and mortality from CABP. CABP is the most common cause of infectious death in U.S. adults age 65 and older. Results of the pooled analysis from the pivotal Phase 3 clinical trials of XENLETA will be presented at the virtual CHEST Annual Meeting, October 18-21, 2020. In this pooled analysis of 1289 patients from LEAP 1 and LEAP 2 by age group, including adults ages 18-64, 65-74, 75-84, and 85 and older, 40 percent of the overall pooled patient population was over 65 years of age. Compared to younger patients, patients 65 years of age and older had higher pneumonia severity scores and were more likely to have renal impairment, cardiac disease, hypertension, diabetes or asthma/COPD. The analysis showed that early clinical response and investigator assessment of clinical response at the Test of Cure for XENLETA were high and similar to that of moxifloxacin, a current standard of care fluoroquinolone for CABP, for all age groups. The adverse event profile and study drug discontinuation rates were similar across all age groups. XENLETA is a first-in-class systemic pleuromutilin antibiotic with a unique mechanism of action that attacks the difficult-to-treat pathogens in CABP and addresses the challenges of antibiotic resistance. It is approved by the FDA for the IV and oral treatment of CABP in adults.

07:04 EDT Gossamer Bio trading halted, news dissemination

07:04 EDT Accenture, Takeda and Amazon enter into a strategic agreement - Takeda Pharmaceutical (TAK), Accenture (ACN) and Amazon (AMZN) Web Services have entered into a five-year strategic agreement to accelerate Takeda's digital transformation. "By combining the power of three organizations, Takeda is making a bold move to be at the intersection of human health, technology and business growth," said Christophe Weber, Takeda president and CEO. In addition, the Plasma-Derived Therapies Business Unit, which develops critical, life-saving and life-sustaining therapies for patients with rare and complex diseases, is creating state-of-the-art, digitally-connected donation centers and modernizing the donor experience, optimizing the plasma collection process. Takeda's plans to increase its plasma collection and manufacturing capacity by at least 65% by 2024 are geared towards expanding access to essential medicines and accelerating new treatments for patients.

07:03 EDT Evelo Biosciences treats first patient in Phase 2 trial of EDP1815 - Evelo Biosciences announced that it has dosed the first patients in its Phase 2 clinical trial evaluating EDP1815 for the treatment of mild to moderate psoriasis. EDP1815 is an investigational oral biologic in development for the treatment of inflammatory diseases including psoriasis, atopic dermatitis, and COVID-19. EDP1815-201 is a double-blind, placebo-controlled, dose-ranging Phase 2 trial designed to evaluate three doses of the enteric capsule formulation of EDP1815 versus placebo in 225 patients with mild to moderate psoriasis over a 16-week treatment period. The primary endpoint is mean reduction in Psoriasis Area and Severity Index score at 16 weeks. Key secondary endpoints include other clinical measures of disease such as Physician's Global Assessment, Body Surface Area, PGA x BSA, Psoriasis Symptom Inventory, Dermatology Life Quality Index, and Lesion Severity Score. Interim data from the study is expected by mid-2021.

06:56 EDT International Game utilizes cashless solution at reopened casino in New York - International Game announced that the company is utilizing its Resort Wallet cashless solution at the newly reopened Resorts World Catskills Casino and Resort in Monticello, New York, a subsidiary of the Genting Group. Resort Wallet gives Resorts World Catskills patrons the option of a contactless, cashless gaming experience. Players can use their physical Resorts World Catskills Players Club card to load cash into a secure digital wallet from either the casino cashier or any slot machine and access those funds from any slot machine.

06:54 EDT Quhuo to acquire 54.22% of Lalai for RMB133M - Quhuo announced that it has entered into a definitive investment agreement to acquire a 54.22% equity interest in Lailai Information Technology, an on-demand workforce platform that specializes in housekeeping solutions for hotels and B&Bs, for a total consideration of approximately RMB133.0M in the form of cash and the Company's securities in aggregate. According to the Agreement, the Company agreed to issue 1,357,759 Class A ordinary shares of the Company to the selling shareholders of Lailai under a private placement pursuant to an exemption or exclusion from the registration requirements under the Securities Act of 1933. The Consideration Shares will be subject to relevant restrictions on transfer. The Company has agreed to repurchase the Consideration Shares or pay the balance of the resale price if the resale price of the Consideration Shares falls below an indicative minimum price within a certain period after the transfer restrictions expire. The parties expect to close the transaction in October, subject to the relevant corporate approvals and customary closing conditions.

06:54 EDT Primo Water subsidiary acquires Mountain Valley Water Company of Los Angeles - Primo Water announced that Primo Water, a wholly-owned subsidiary of Primo, has acquired substantially all of the assets of Mountain Valley Water Company of Los Angeles, or MVLA. MVLA has been a provider of water delivery services to homes and offices in the Los Angeles area since its founding in 1983, and is the largest distributor of Mountain Valley in the U.S. The acquisition will add over 8,000 customers to Primo NA, increasing its footprint in southern California. Customers of MVLA will continue to be offered Mountain Valley Spring Water and can also now enjoy Sparkletts, the Primo water brand in the region, and have the ability to select additional products for their orders, including coffee and tea, sparkling water beverages from Sparkling Ice as well as other water products.

06:51 EDT JPMorgan reports AUM of $2.6T, up 16%

06:49 EDT JPMorgan reports Q3 provision for credit losses $611M

06:48 EDT JPMorgan reports Q3 ROE 15%, ROTCE 19%

06:46 EDT Genmab announces Q3 sales of Darzalex were $1.099B - Genmab (GMAB) announced that worldwide net trade sales of DARZALEX, or daratumumab, including sales of the subcutaneous formulation, as reported by Johnson & Johnson (JNJ) were $1.099B in the Q3. Net trade sales were $85M in the U.S. and $514M in the rest of the world. Genmab receives royalties on the worldwide net sales of DARZALEX and DARZALEX FASPRO under the exclusive worldwide license to Janssen Biotech, to develop, manufacture and commercialize daratumumab. As previously announced, Janssen has started reducing its royalty payments to Genmab by what it claims to be Genmab's share of Janssen's royalty payments to Halozyme, (HALO) company announcement No. 39 of September 22.

06:38 EDT Ovintiv announces start-up of Pipestone Processing Facility - Ovintiv announced the start-up of the Pipestone Processing Facility, or PPF, a natural gas processing and liquids stabilization plant supporting the company's high-return, condensate-rich Montney development. Ovintiv managed the PPF's design and construction and delivered its start-up more than five months ahead of its original schedule and at budgeted costs. The start-up of the PPF provides Ovintiv with additional net processing capacity of approximately 170 MMcf/d of natural gas and 19,000 bbls/d of liquids, primarily condensate. The start-up of the PPF required no new drilling to satisfy new capacity arrangements. The facility allows Ovintiv to maximize its existing volumes and optimize midstream fees by routing production to gathering systems with lower line pressures, as well as the capacity to grow its Pipestone Montney resources. The PPF, which is owned by Keyera Partnership, a subsidiary of Keyera, provides Ovintiv with processing under a "fee-for-service" midstream agreement. Ovintiv has employed this development model in other recent midstream expansions. These agreements provide increased financial flexibility with a limited financial obligation of a revenue guarantee on a fraction of its initial capacity rights.

06:32 EDT Babcock & Wilcox Renewable announces partnership with Eos Energy Storage - Babcock & Wilcox, through its B&W Renewable segment, has signed a strategic partnership agreement with Eos Energy Storage to sell and service Eos' innovative, patented Eos Znyth zinc battery solution for industrial and utility-scale energy storage. Under this agreement, B&W subsidiary The Babcock & Wilcox Company will market and sell this pioneering battery technology to its customers worldwide and B&W subsidiary Babcock & Wilcox Construction Co. will serve as Eos' exclusive preferred installation provider for the technology in the U.S. and Canada. Under the agreement, B&W will market the Znyth zinc battery storage solution to its global customer base, including industrial customers such as refineries and pulp and paper plants, as well as utility and power customers. In addition, B&W will immediately begin collaborating with Eos on installation, commissioning and maintenance scope for projects in Eos' robust pipeline.

06:18 EDT BlackRock reports Q3 quarterly net inflows $129B - Reports $129B of quarterly total net inflows, led by continued momentum in fixed income and cash management, with positive flows across all regions, investment styles and product types.

06:05 EDT MVC, Dynavax report Taiwan government subsidy for COVID-19 vaccine with CpG 1018 - Medigen Vaccine Biologics, or MVC, and Dynavax announced that MVC has obtained a Taiwan government subsidy for successfully initiating a Phase 1 clinical trial in Taiwan. The first participant in MVC's Phase 1 clinical trial was dosed with MVC's COVID-19 vaccine combined with Dynavax's CpG 1018 adjuvant at National Taiwan University Hospital in early October. The subsidy will be released at agreed upon milestones in the total amount of up to $16.4M. The grant received by MVC was earmarked by the Taiwan government for purposes of research and development of a locally produced COVID-19 vaccine. MVC's Phase 1 study is an open-label, single-center, staggered dose-escalation study intended to assess the safety and immunogenicity of the stable prefusion form of SARS-CoV-2 recombinant spike protein S-2P at three dose levels adjuvanted with CpG 1018 plus alum, in approximately 45 healthy subjects 20 to 50 years of age. The vaccination schedule consists of two doses for each study participant, administered via intramuscular injection 28 days apart, on Day 1 and Day 29.

06:02 EDT Inozyme names Yves Sabbagh, Ph.D., as Chief Scientific Officer - Inozyme Pharma announced the appointment of Yves Sabbagh, Ph.D., as senior vice president and chief scientific officer, and the retirement of David Thompson, Ph.D., Inozyme's former chief scientific officer. Dr. Sabbagh brings to Inozyme more than 20 years of experience in rare genetic disorders and mineral metabolism with responsibilities leading to the identification and evaluation of novel therapeutic approaches and translating them into clinical candidates. Dr. Sabbagh will be responsible for expanding Inozyme's proprietary pipeline by identifying and developing new therapeutics for monogenic and non-genetic diseases of abnormal mineralization.

06:01 EDT Mesoblast: Phase 3 trial of remestemcel-L surpasses 50% enrollment - Mesoblast announced that the randomized controlled Phase 3 trial of remestemcel-L on top of maximal care in ventilator-dependent patients with acute respiratory distress syndrome due to COVID-19 infection has surpassed 50% enrollment. The trial's primary endpoint is reduction in 30-day mortality relative to maximal care. ARDS continues to be the primary cause of death in COVID-19 patients. Mesoblast Chief Medical Officer Dr Fred Grossman said: "There is an urgent need for targeted treatments to reduce the continued high mortality in COVID-19 ARDS patients who are dependent on mechanical ventilators. We expect to complete the enrollment target in this important trial by the end of the year as the enrollment rate continues to increase in line with the surge in new infections across the United States."

05:32 EDT Nokia to provide Chunghwa Telecom with products to support 5G coverage - Nokia announced that it will provide Taiwanese mobile operator, Chunghwa Telecom, or CHT, with a range of products from its small cells portfolio to support CHT's initiative to deliver 5G coverage. CHT is the first operator in Taiwan to deploy a 5G non-standalone, or NSA, small cells solution enabling instant 5G coverage in specific areas such as business as well as tourist districts. Nokia has already commenced deployment and has installed 140 5G small cells to date. Nokia has been a partner of CHT, since the 2G era. The deal will see Nokia supply CHT with its AirScale indoor Radio, or ASiR, solution for indoor coverage and capacity, as well as its AirScale micro RRH for outdoor and urban hot spots. These will be deployed to complement the existing base of over 2,500 sets of 4G small cells. CHT is working closely with local small to medium-size enterprises to provide secure 5G coverage to enable industry 4.0 automation.

05:25 EDT Broadridge selected by Britannia Global for post-trade securities options - Broadridge announced that Britannia Global Markets, a brokerage house and subsidiary of Britannia Financial Group, has selected Broadridge to streamline its post-trade processing for its international securities business including cash equities, fixed income and repurchase agreements. Broadridge's solution will provide Britannia Global Markets with a strategic, multi-market platform with the scale to support growth and respond to regulatory requirements. It will be deployed as a SaaS-based solution that enables the firm to benefit from a service that mitigates risk and underpins a superior client service.

05:16 EDT Regeneron, Sanofi announce Dupixent trial met primary and secondary endpoints - Regeneron (REGN) and Sanofi (SNY) announced that a pivotal Phase 3 trial of Dupixent met its primary and all key secondary endpoints in children aged six to 11 years with uncontrolled moderate-to-severe asthma. In a broad type 2 inflammatory asthma patient population, defined as having elevated eosinophils, or EOS, or elevated fractional exhaled nitric oxide, or FeNO, Dupixent added to standard of care significantly reduced asthma attacks and improved lung function as early as two weeks after the first dose, compared to standard of care alone. More than 90% of children in the trial had at least one concurrent type 2 inflammatory condition including atopic dermatitis and eosinophilic esophagitis. Safety results from the trial were generally consistent with the known safety profile of Dupixent in patients aged 12 years and older with moderate-to-severe asthma. The primary endpoint assessed the annualized rate of severe asthma attacks in two primary pre-specified populations: patients with baseline blood EOS greater than or equal to300 cells/mul and patients with markers of type 2 inflammation. Across these two patient groups respectively, those who added Dupixent to standard of care experienced: Reduced rate of severe asthma attacks, with a 65% and 59% average reduction over one year compared to placebo (0.24 and 0.31 events per year for Dupixent vs. 0.67 and 0.75 for placebo, respectively). Improved lung function at 12 weeks compared to baseline by 10.15 and 10.53 percentage points for Dupixent vs. 4.83 and 5.32 percentage points for placebo, respectively, as measured by percent predicted FEV1, or FEV1pp. This is a common endpoint in pediatric asthma trials to evaluate a patient's change in lung function compared to their predicted lung function based on a number of factors including age, height and sex, to account for children's growing lung capacity at different stages of development. This clinically meaningful improvement in lung function was observed as early as two weeks and was sustained for up to 52 weeks. The safety results from the trial were generally consistent with the known safety profile of Dupixent in patients aged 12 years and older with moderate-to-severe asthma. Over one year, overall rates of adverse events were 83% for Dupixent and 80% for placebo. Adverse events that were most commonly observed with Dupixent versus placebo included injection site reactions, viral upper respiratory tract infections and eosinophilia. Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4, or IL-4, and interleukin-13, or IL-13, proteins, that was invented using Regeneron's proprietary VelocImmune technology. Data from Dupixent clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in asthma, chronic rhinosinusitis with nasal polyposis, atopic dermatitis and eosinophilic esophagitis.

05:07 EDT PG&E notifies customers in 21 counties of potential public safety power shutoff - PG&E has notified customers in targeted portions of 21 counties about a potential public safety power shutoff, or PSPS, as early as Wednesday afternoon. Hot and dry conditions combined with expected high wind gusts pose an increased risk for damage to the electric system that has the potential to ignite fires in areas with dry vegetation. High fire-risk conditions are expected to arrive Wednesday evening. High winds are currently expected to subside Thursday morning in some locations and Friday morning in other locations. PG&E will then inspect the de-energized lines to ensure they were not damaged during the wind event. PG&E will safely restore power as quickly as possible, with the goal of restoring most customers within 12 daylight hours, based on current weather conditions.